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In going on with these Experiments how many pretty Systems do we build which 
we soon find ourselves oblig’d to destroy…it may help to make a vain man 
humble. 
BENJAMIN FRANKLIN 
(1706-1790) 
 
 
 
 
Illness is the night side of life, a more onerous citizenship. Everyone who is born 
holds dual citizenship, in the kingdom of the well and in the kingdom of the sick. 
Although we all prefer to use the good passport, sooner or later each of us is 
obliged, at least for a spell, to identify ourselves as citizens of that other place. 
  SUSAN SONTAG, Illness as Metaphor 
 (1933-2004) 
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ABSTRACT 
 The perivascular adventitia (PA) senses and responds to injuries in blood 
vessels and the tissues they feed. Cells in the PA form the outermost vascular 
layer, joining the circulatory system to other organs. Housing hematopoietic, 
mesenchymal and neuronal cells allows flexible adventitial responses to diverse 
perturbations. However, the PA response can also be pathogenic. Thickening of 
the adventitia may drive ischemia and hypertension. It can also be a niche for local 
lymphocyte priming in diseases such as idiopathic pulmonary arterial 
hypertension. Despite their importance, PA contributions to skin diseases were 
understudied. 
 The hypothesis that contrasting two cutaneous diseases, scleroderma and 
discoid lupus erythematosus (DLE), would illuminate discrete PA alterations was 
explored. Vascular changes are prominent, but distinct, in both diseases. Studying 
perivascular adventitial changes in these diseases may yield insights into both 
dermal and vascular pathologies. PA fibroblasts in healthy human skin were 
phenotypically distinct from the surrounding dermal fibroblasts. In both 
scleroderma and DLE, PA fibroblasts expanded and expressed surface markers 
  ix 
not observed in healthy skin including vascular cell adhesion molecule 1 (VCAM1), 
podoplanin (PDPN) and the p75 low affinity nerve growth factor receptor (NGFR). 
Elaborated networks of PA fibroblasts in DLE expressed VCAM1 and enmeshed 
dense, T cell-rich infiltrates. Transcriptional analyses indicated positive 
correlations between VCAM1, T cell chemoattractants and interleukin (IL)-15, 
which promotes their survival. Activated PA fibroblasts in DLE likely create a 
supportive niche for T cells infiltrating the skin. 
 In contrast, enlarged PA fibroblast networks in scleroderma expressed 
NGFR in the absence of leukocyte infiltrates. This PA fibroblast phenotype was 
shared among reparative and pathologic scarring, and four dermal tumors. NGFR 
is a mesenchymal stem cell (MSC) marker, and expanded NGFR+ mesenchymal 
cells were immediately adjacent to cluster of differentiation (CD)34+ and CD73+ 
PA MSC. Expression of NGFR by PA fibroblasts is likely associated with reparative 
responses. Different stimuli induced VCAM1 and NGFR on cultured human dermal 
fibroblasts, supporting these as discrete activation states. In conclusion, these 
studies demonstrated the responsive and plastic nature of human dermal PA 
mesenchymal cells, and pointed to connections with vascular alterations in skin 
diseases. 
  
  x 
TABLE OF CONTENTS 
 
DEDICATION ....................................................................................................... v 
ACKNOWLEDGMENTS .......................................................................................vi 
ABSTRACT ........................................................................................................ viii 
TABLE OF CONTENTS ....................................................................................... x 
LIST OF TABLES ............................................................................................... xiv 
LIST OF FIGURES ..............................................................................................xv 
LIST OF ABBREVIATIONS ............................................................................... xvii 
CHAPTER ONE: INTRODUCTION ...................................................................... 1 
Scleroderma and Discoid Lupus Erythematosus Skin Diseases ....................... 1 
Scleroderma and Systemic Sclerosis ............................................................ 3 
Discoid Lupus Erythematosus ....................................................................... 5 
Vascular Pathology in SSc and DLE ................................................................. 7 
Adventitial Thickening in SSc ........................................................................ 9 
Perivascular Cuffing in DLE ......................................................................... 11 
PA Mesenchymal Cells in SSc and DLE ......................................................... 13 
Potential Roles for PA Mesenchymal Cells in SSc ...................................... 14 
PA Fibroblast Support of Leukocytes in DLE ............................................... 15 
Central Hypothesis and Summary of Results.................................................. 16 
CHAPTER TWO: MATERIALS AND METHODS ............................................... 18 
  xi 
Tissue Samples .............................................................................................. 18 
Histology ......................................................................................................... 22 
Gene Expression Data and Analysis ............................................................... 25 
Cell Culture ..................................................................................................... 27 
Flow Cytometry ............................................................................................... 27 
Statistics.......................................................................................................... 28 
CHAPTER THREE: PERIVASCULAR ADVENTITIAL FIBROBLAST 
SPECIALIZATION ACCOMPANIES T CELL RETENTION IN THE INFLAMED 
HUMAN DERMIS ............................................................................................... 30 
Abstract ........................................................................................................... 30 
Introduction ..................................................................................................... 31 
Results ............................................................................................................ 34 
Defining the Perivascular Adventitial Compartment in Normal, SSc and DLE 
Skin ............................................................................................................. 34 
VCAM1 Display on Activated Perivascular Adventitial Fibroblasts .............. 38 
Dermal Perivascular T Cell Infiltrates Localize to VCAM1+ Vascular 
Adventitia ..................................................................................................... 41 
VCAM1 RNA Levels Correlate with T Cell Accumulation ............................ 44 
Perivascular T Cell Accumulation Can Occur in the Absence of PDPN+ PA 
Fibroblasts ................................................................................................... 48 
Do VCAM1+ PA Fibroblasts Resemble FRC? ............................................. 51 
  xii 
Is the PA Compartment a “Perivascular Cuff” or a Tertiary Lymphoid 
Structure? .................................................................................................... 53 
Comparison of Murine and Human PA Compartments ............................... 56 
Discussion....................................................................................................... 61 
CHAPTER FOUR: NERVE GROWTH FACTOR RECEPTOR EXPRESSION 
IDENTIFIES AN EXPANDED DERMAL PERIVASCULAR STROMAL CELL IN 
SYSTEMIC SCLEROSIS AND WOUND HEALING ............................................ 67 
Abstract ........................................................................................................... 67 
Introduction ..................................................................................................... 68 
Results ............................................................................................................ 71 
Rare Perivascular Cells Expressing NGFR in Healthy Human Skin are More 
Frequent and Cover Greater Area in SSc.................................................... 71 
Human Dermal PA Cells Expressing NGFR are Mesenchymal ................... 75 
Relationships Between NGFR+ PA Cells and Adventitial MSC ................... 77 
Perivascular NGFR-Expressing Cells are More Frequent and Occupy Larger 
Areas in Human Reparative and Pathologic Dermal Scarring than Healthy 
Skin ............................................................................................................. 79 
NGFR Expression in the Hypodermis During Early Wound Healing in Mice 81 
Perivascular NGFR Expression is Common in Four Types of Dermal Tumors
 .................................................................................................................... 83 
Expanded PA Fibroblasts in SSc and DLE Distinguished by NGFR and 
VCAM1 Expression ..................................................................................... 85 
  xiii 
Polar Solvents Induce NGFR, While the Combination of TNF and IFNγ 
Stimulates VCAM1 Expression by Cultured Primary Human Dermal 
Fibroblasts ................................................................................................... 87 
Discussion....................................................................................................... 91 
CHAPTER FIVE: CONCLUDING REMARKS ..................................................... 97 
Summary of Results and Integration with the Literature ................................. 97 
Mesenchymal Cell Heterogeneity and PA Fibroblast Functions in Healthy 
Skin ........................................................................................................... 100 
Expansion and Activation of PA Fibroblasts in DLE and Dermatitis .......... 103 
Expansion of NGFR+ PA Mesenchymal Cells in SSc, Wound Healing and 
Fibromas ................................................................................................... 107 
Limitations ..................................................................................................... 111 
APPENDIX: COPYRIGHT PERMISSION ......................................................... 113 
BIBLIOGRAPHY ............................................................................................... 117 
CURRICULUM VITAE ...................................................................................... 171  
  
  xiv 
LIST OF TABLES 
Table 1. Characteristics of healthy, SSc, CSD, AD and DLE patients whose 
biopsies were studied in Chapter Three. ..................................................... 20 
Table 2. Characteristics of healthy, SSc, DLE and reparative and pathologic scar 
patients whose biopsies were studied in Chapter Four. .............................. 21 
Table 3. Antibodies used for histology. ............................................................... 25 
Table 4. Antibodies used for flow cytometry. ...................................................... 29 
Table 5. VCAM1 RNA is positively correlated with CD3G, IL-15 and CCL19 RNA 
in SSc, AD and DLE. ................................................................................... 46  
  
  xv 
LIST OF FIGURES 
Figure 1. Layers of the vascular unit wall. ............................................................ 8 
Figure 2. Perivascular adventitial fibroblasts express CD90. .............................. 36 
Figure 3. PA CD90+, VCAM1+ and PDPN+ cells are PDGFRβ+ fibroblasts. ..... 37 
Figure 4. VCAM1 expression defined a different state of the perivascular 
adventitia. .................................................................................................... 41 
Figure 5. Dense perivascular T cell infiltrates are found within VCAM1+ PA 
fibroblast networks. ..................................................................................... 43 
Figure 6. VCAM1 RNA correlates with T cell infiltration, ITGA4, and IL15, but not 
IL7 RNA. ...................................................................................................... 45 
Figure 7. Perivascular T cell infiltrates occur regardless of PA fibroblast PDPN 
expression. .................................................................................................. 50 
Figure 8. VCAM+SMA- PA fibroblasts associated with MFAP5+ fibers. ............. 52 
Figure 9. Perivascular structures in SSc, CSD, and DLE are not mature TLS. .. 54 
Figure 10. PA compartment in mouse skin. ........................................................ 57 
Figure 11. T cells co-localized with VCAM+ perivascular stromal cells in the 
diabetic NOD pancreas and the livers of gld.ApoE mice. ............................ 60 
Figure 12. NGFR expression in healthy human skin. ......................................... 72 
Figure 13. Perivascular cells expressing NGFR are more frequent and cover 
larger areas in the skin of SSc patients. ...................................................... 74 
Figure 14. Perivascular adventitial NGFR+ cells are mesenchymal. .................. 76 
Figure 15. Relationship between NGFR+ PA cells and PA MSC. ...................... 78 
  xvi 
Figure 16. Expansion of perivascular cells expressing NGFR in reparative and 
pathologic scars. ......................................................................................... 80 
Figure 17. NGFR+ cells appear in the murine hypodermis 4 days post-incisional 
wound in skin adjacent to the wound. .......................................................... 82 
Figure 18. Patterns of NGFR expression in four dermal tumors. ........................ 84 
Figure 19. PA fibroblasts expressing NGFR in SSc and VCAM1 in DLE are in 
distinct states. .............................................................................................. 86 
Figure 20. Polar solvents induce NGFR expression by primary human dermal 
fibroblasts, whereas the combination of TNF and IFNγ stimulates VCAM1 
and ICAM1 production without altering CD90. ............................................. 90 
Figure 21. Model of PA mesenchymal cell phenotypes and layers observed in 
affected SSc skin. ........................................................................................ 93 
Figure 22. Proposed model of PA fibroblast activation states in DLE and SSc. . 99 
 
  
  xvii 
LIST OF ABBREVIATIONS 
AD ................................................................................................ atopic dermatitis 
AFX .................................................................................... atypical fibroxanthoma 
AP .......................................................................................... alkaline phosphatase 
BMP ............................................................................... bone morphogenic protein 
CCL2 ......................................................................... CC motif chemokine ligand 2 
CCL17 ..................................................................... CC motif chemokine ligand 17 
CCL19 ..................................................................... CC motif chemokine ligand 19 
CCL21 ..................................................................... CC motif chemokine ligand 21 
CCR2 ..................................................................... CC motif chemokine receptor 2 
CCR7 ..................................................................... CC motif chemokine receptor 7 
CXCL9 .................................................................... CXC motif chemokine ligand 9 
CXCL10 ................................................................ CXC motif chemokine ligand 10 
CXCL11 ................................................................ CXC motif chemokine ligand 11 
CXCL12 ................................................................ CXC motif chemokine ligand 12 
CXCL13 ................................................................ CXC motif chemokine ligand 13 
CXCR3 ................................................................ CXC motif chemokine receptor 3 
CSD ........................................................................... chronic spongiotic dermatitis 
DC ...................................................................................................... dendritic cell 
DF .................................................................................................. dermatofibroma 
DFSP ................................................................ dermatofibrosarcoma protuberans 
DLE ........................................................................... discoid lupus erythematosus  
  xviii 
DMF .......................................................................................... dimethylformamide 
DMSO ......................................................................................... dimethyl sulfoxide 
dpw .............................................................................................. days post-wound 
dSSc ............................................................................... diffuse systemic sclerosis 
ECM ......................................................................................... extracellular matrix 
EGF ................................................................................... epidermal growth factor 
FACS ................................................................. fluorescence activated cell sorting 
FDC ...................................................................................... follicular dendritic cell 
FGF2 ............................................................................... fibroblast growth factor 2 
FRC ................................................................................... fibroblastic reticular cell 
GEO ............................................................................... gene expression omnibus 
gld.ApoE ............................................................................................ Faslgld.apoE-/- 
HEV .................................................................................... high endothelial venule 
HRP ................................................................................... horseradish peroxidase 
HS ............................................................................................... hypertrophic scar 
ICAM1 ................................................................ Intercellular adhesion molecule 1 
IFNγ ....................................................................................................... interferon γ 
IL-4 ...................................................................................................... interleukin-4 
IL-7 ...................................................................................................... interleukin-7 
IL-13 .................................................................................................. interleukin-13 
IL-15 .................................................................................................. interleukin-15 
IL-17A ............................................................................................. interleukin-17A 
  xix 
ILC ........................................................................................... innate lymphoid cell 
ITGA4 .................................................................................................... integrin α4 
KS .......................................................................................................... keloid scar 
LFA1 ......................................................... leukocyte function-associated antigen 1 
lSSc ................................................................................ limited systemic sclerosis 
LTβR ................................................................................... lymphotoxin-β receptor 
MCAM .............................................................. melanoma cell adhesion molecule 
MFAP5 ............................................................... Microfibrillar-associated protein 5 
MFI .......................................................................... median fluorescence intensity 
MMP ................................................................................ matrix metalloproteinase 
MRL/lpr ....................................................................................... MRL/MpJ-Faslpr/J 
MRSS ......................................................................... modified Rodnan skin score 
MSC .................................................................................. mesenchymal stem cell 
NGF .......................................................................................... nerve growth factor 
NGFR ................................................ p75 low affinity nerve growth factor receptor 
NOD ................................................................... non-obese diabetic (NOD/ShiLtJ) 
PA ........................................................................................ perivascular adventitia 
PAH ...................................................................... pulmonary arterial hypertension 
PBS ............................................................................... phosphate-buffered saline 
PDGF ....................................................................... platelet-derived growth factor 
PDGFRβ .................................................. platelet-derived growth factor receptor β 
PDPN ................................................................................................... Podoplanin 
  xx 
PNAd .................................................................. peripheral lymph node addressin 
RP ....................................................................................Raynaud’s phenomenon 
RS ................................................................................................... reparative scar 
SELE ....................................................................................................... E-selectin 
SELP ....................................................................................................... P-selectin 
SMA ...................................................................................  α-smooth muscle actin 
SSc ............................................................................................ systemic sclerosis 
TBS ........................................................................................... tris-buffered saline 
TBST ............................................................................. TBS with 0.05% tween-20 
TGFβ .......................................................................... transforming growth factor β 
TH1 ............................................................................................ type 1 T helper cel 
TLS ............................................................................... Tertiary lymphoid structure 
TNF .................................................................................... tumor necrosis factor α 
Treg ............................................................................................... regulatory T cell 
TrkA .......................................................... neurotrophic receptor tyrosine kinase 1 
UCHL1 ....................................................... ubiquitin carboxyl-terminal esterase L1 
VCAM1 ............................................................. Vascular cell adhesion molecule 1 
VLA4 .......................................................................................... very late antigen 4 
VSMC ......................................................................... vascular smooth muscle cell 
  
  
1 
CHAPTER ONE: INTRODUCTION 
Scleroderma and Discoid Lupus Erythematosus Skin Diseases 
Every year approximately 85 million Americans (25% of the US population) 
seek treatment for skin diseases costing $75 billion (1). The resulting shame and 
social stigma frequently cause depression in these patients (2). Effective 
treatments for skin diseases have outsized benefits for patients’ quality of life. 
Cutaneous disorders may be restricted to the skin or associated with systemic 
disease (3–6). Morbidities associated with skin diseases are frequently less severe 
than those for systemic diseases; correspondingly, the safety demanded of 
therapies is higher than for more physically severe diseases, such as multiple 
sclerosis. Developing effective drugs that meet this rigorous safety profile requires 
a detailed understanding of the contributing cells and their disease-specific 
changes.  
Understanding the cellular and molecular drivers of disease has led to the 
development of powerful and safe therapies for some skin diseases, such as 
interleukin-17A (IL-17A) blockade for psoriasis (7). Other skin diseases still await 
such treatments. Scleroderma and discoid lupus erythematosus (DLE) are two 
such diseases. Targeted treatments, such as blocking IL-17A, and 
microenvironment-modifying drugs, which deactivate the niche that supports 
pathogenic cells, may circumvent the adverse effects of the generalized 
immunosuppressants and chemotherapeutics currently prescribed for 
scleroderma and DLE patients (8–10). Although the end-stage skin lesions of both 
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scleroderma and DLE can be called scars, the cutaneous presentations are 
clinically and microscopically distinct (11, 12). Scleroderma scars are likely caused 
by ischemia and fibrosis, while DLE scars are thought to result from autoimmune 
attack upon cells of the epidermis and dermis. Contrasting diseases with such 
distinct pathologies is one method of identifying discrete microenvironments and 
potential therapeutic targets.  
Comparing scleroderma and DLE can illuminate both conditions. Disease-
associated cutaneous alterations can be identified by contrasting healthy and 
affected skin. Similarly, distinctions between clinically divergent diseases can 
discriminate between changes related to a specific manifestation and those 
common to many forms of sickness. For example, large T cell infiltrates are 
common in DLE, but not SSc, skin lesions leading to the hypothesis that 
autoimmune attack by T cells against cutaneous cells causes the atrophy seen in 
end-stage DLE scars (13–17). Conversely, increased levels of the chemokine CC 
motif chemokine ligand (CCL)2, are shared between the two diseases (13, 18) 
suggesting that CCL2 may be a general signal of sickness unrelated to disease 
pathogenesis. Indeed, several clinical trials of antibodies blocking CCL2 or its 
receptor, CCR2, in cancer and inflammatory diseases have either had little 
success or demonstrated enhanced metastasis upon withdrawal (19–22). 
Contrasting scleroderma, DLE and healthy skin may identify cutaneous changes 
specifically associated with fibrosis or inflammatory destruction that point to safer 
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drug targets than those manipulated by immunosuppressants and cytotoxic 
therapies. 
Scleroderma and Systemic Sclerosis 
Scleroderma is a heterogeneous disease with the ultimate shared features 
of vascular pathology, immunological dysfunction and skin hardening (i.e. 
sclerosis) (11). Although scleroderma specifically refers to skin fibrosis, it occurs 
in over 90% of patients with the broader disease systemic sclerosis (SSc) (23). All 
of the patients studied herein had both systemic and cutaneous disease, so I will 
use SSc. SSc patients can be further subdivided into those with limited (lSSc) or 
diffuse (dSSc) cutaneous sclerosis. Estimates indicate that lSSc represents 60-
80% of cases (24). Patients with limited disease have skin fibrosis restricted to 
their extremities, whereas diffuse disease also occurs on the trunk (25). 
Prevalence data for SSc in the United States estimate 276 cases occur per 
million adults. Five women are affected for every man. Most female SSc patients 
are diagnosed in middle age (24, 26). While SSc is rare, the associated internal 
organ fibrosis and lack of effective treatments make it one of the deadliest 
rheumatic diseases (27). The median survival for SSc patients is 11 years after 
diagnosis (28). 
The etiology of SSc is unclear. Given the clinical heterogeneity of SSc, it is 
likely that there are several pathologic paths that end in similar manifestations (23, 
29, 30). Clinically, vascular dysfunction precedes cutaneous fibrosis in most 
patients (11, 23). One hypothesis is that vascular injury leads to perivascular 
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infiltration by monocytes or macrophages that activate surrounding fibroblasts 
(31). Activated fibroblasts thicken the skin by depositing and crosslinking 
extracellular matrix (ECM) proteins. As a result, affected areas adopt a plump and 
shiny or waxy appearance (11). Skin thickening in SSc is measured using the 
modified Rodnan skin score (MRSS), where a physician pinches 17 areas on a 
patient’s body and records a score from zero to three, with three being the most 
severe thickening (32). 
Apoptotic endothelial cells are frequently detected in the skin of SSc 
patients prior to fibrosis (17, 33, 34). Anti-endothelial cell autoantibodies, ischemia, 
reperfusion-induced reactive oxygen species and environmental toxins have all 
been proposed to trigger endothelial cell apoptosis, although there is scant data 
for most of these hypotheses (27, 35–38). Leukocyte infiltrates in SSc skin are 
generally dominated by macrophages, which may activate fibroblasts by secreting 
transforming growth factor-β (TGFβ) and platelet-derived growth factors (PDGFs) 
(16, 17, 39, 40). Fibroblasts in SSc may also be activated by other cytokines, such 
as IL-4 and IL-13, but the sources of these molecules remain controversial (41–
44). Collectively, these observations signify the complex pathogenesis of SSc and 
likely represent one of many potential routes. 
The complexity and relatively short median survival time for SSc patients 
are reflected in the lack of US Food and Drug Administration-approved treatments 
(45). Calcium channel blockers, phosphodiesterase type 5 inhibitors and 
intravenous prostanoids all moderately reduce symptoms of vascular constriction, 
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but only in subsets of patients (6, 46). For patients not aided by these drugs, the 
only other option is radical sympathectomy (47–49). Much is known about changes 
in endothelial and vascular smooth muscle cells, but fewer studies have examined 
other blood vessel-associated cells. A better understanding of changes in blood 
vessels may aid the development of treatments for SSc vascular disease that also 
improve ischemic injuries and fibrosis. 
Discoid Lupus Erythematosus 
Unlike SSc, active DLE lesions are overtly inflamed. These lesions are 
frequently covered by a crust and, over time, become sunken and atrophic. DLE 
is more clinically uniform than SSc. This is due, in part, to discrete definitions of 
three types of cutaneous lupus. Chronic cutaneous lupus erythematosus is one of 
these, and DLE is its most common subtype (12).  
Prevalence estimates for DLE range from 280 to 780 per million adults, (50, 
51). Similar to SSc, DLE has a female:male ratio of approximately 2:1, and the 
average onset of DLE is in the early 30’s, a decade earlier than SSc (3, 51). While 
DLE patients are at slightly higher risk for squamous cell carcinoma, direct 
mortality is less of a concern than psychological distress (52). Data on the median 
survival time from diagnosis is unavailable for these patients, but appears to be 
longer than 25 years (3). 
Relatively few DLE patients develop systemic disease. About 75% of 
patients present with localized DLE, where lesions are restricted to the head and 
neck. The remaining patients develop lesions anywhere on their skin (generalized 
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DLE). Only 5% of localized and 20% of generalized DLE patients manifest 
systemic involvement (4, 53, 54). Low risk of internal organ complications in DLE 
patients also sets this disease apart from SSc.  
The etiology of DLE is unclear. Studies indicate that the epithelial cells of 
some DLE patients produce high levels of inflammatory cytokines in response to 
UV light (55–58) (reviewed by (59)). Inflammation induces adhesion molecules on 
endothelial cells and the production of chemokines throughout the skin (60, 61). 
These changes allow lymphocytes, such as cytotoxic CD8 and type 1 helper CD4 
T (TH1) cells, to extravasate into the skin (13–15). Within DLE lesions, leukocytes 
are highly concentrated at the dermo-epidermal junction, and around hair follicles 
and blood vessels (12, 62). Epithelial cells produce the chemokines CXC motif 
chemokine ligand 9-11 (CXCL9-11) and CC motif chemokine ligand 17 (CCL17) 
to attract invading leukocytes, but why these cells accumulate around blood 
vessels is unknown (63, 64).  
There are no US Food and Drug Administration-approved treatments for 
any variation of cutaneous lupus (65). Treatments for DLE, primarily steroids and 
immunosuppressants, reflect our lack of understanding of the etiology. Few clinical 
studies of DLE treatments have been published, and even fewer of these were 
well-powered, randomized and placebo-controlled trials (66). The available data 
suggest that even the best of these treatments, oral hydroxychloroquine, 
completely resolves only ~50% of lesions (67). These medications work by 
blocking leukocyte activation and proliferation. However, given the risks of 
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generalized immunosuppression, DLE patients need drugs that are both more 
effective and targeted. 
An alternative approach is modifying the microenvironment that promotes 
leukocyte accumulation in the skin. Several layers of regulation govern leukocyte 
numbers in inflamed tissues: extravasation out of the blood, survival within the 
inflamed skin and signals that promote or prevent retention or egress (68, 69). 
Therapies that block leukocyte entry, reduce survival or promote exit from the 
inflamed skin by targeting non-leukocytes may halt damage.  
Vascular Pathology in SSc and DLE 
Vessels carrying both blood and lymph are critically important to maintaining 
dermal homeostasis. Blood vessels can have up to three layers: the intima, media 
and adventitia (Figure 1). Endothelial cells line the blood vessel lumen, and 
together with abluminal pericytes, to which they are joined by peg-socket contacts, 
comprise the vascular intima (70). Wrapping the intima are vascular smooth 
muscle cells (VSMC), which constitute the medial layer. The outer-most vascular 
layer is the adventitia. Several cell types, including fibroblasts, leukocytes, nerves 
and MSC cohabitate in this ECM-rich compartment (71–73). Although the blood 
vasculature in human skin, especially capillaries, can appear as individual vessels 
it is more common to find at least two (and often more) vessels bundled together 
into a plexus (74). Due to the complex vascular layers and frequent clustering of 
blood vessels, I will use the term “vascular unit” to refer to these structures.   
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Figure 1. Layers of the vascular unit wall. 
Blood vessels can have up to three layers: the intima, media and adventitia. 
Endothelial cells create the vascular lumen and adhere to a basement membrane 
interwoven with pericytes. This innermost layer is the tunica intima. Vascular 
smooth muscle cells in the tunica media wrap the intima, provide structural 
support and control vascular tone. The outermost layer, the tunica adventitia, is 
a complex, connective tissue-rich layer that anchors the blood vessel to the 
surrounding tissue. Fibroblasts, MSC, leukocytes and the tips of neuronal axons 
are all found in the adventitia. Here, the border between the vascular unit and 
surrounding dermis is indicated by the oval with surrounding dermal fibroblasts 
shown outside of the adventitia. Cells are drawn to show their relative positions 
within the vessel wall, but are not shown to scale. 
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For SSc patients, the transport of oxygen and nutrients to the skin are both 
important functions of blood vessels. Ischemia, or starvation of the skin by vascular 
constriction or other blockage of flow, occurs in approximately 95% of SSc patients 
(23, 75). Blood vessels also facilitate immunological surveillance of the skin by 
transporting leukocytes from lymphoid tissues to sites of inflammation (69). The 
perivascular space may also serve as a niche for local priming of infiltrating 
leukocytes in the skin. Both of these are likely important for the pathogenesis of 
DLE. Although the immune system may also contribute to SSc, the large disparity 
in cutaneous leukocyte infiltration between SSc and DLE patients suggests a more 
central role in DLE. Perhaps the distinct vascular pathologies in SSc and DLE 
influence the disparate dermal manifestations of these diseases and provide clues 
for treatments. 
Adventitial Thickening in SSc 
Raynaud’s phenomenon (RP), where the fingers become blanched and 
numb due to reduced blood flow followed by pain upon reperfusion, occurs in ≥90% 
of SSc patients (23). It often precedes the onset of fibrosis by months or years, 
suggesting a causal link between RP and fibrosis (23). This frequency and timing 
of vascular pathology in SSc patients led LeRoy to propose his vascular hypothesis 
in 1975: macrophage activation or monocyte infiltration into the adventitia induces 
proliferation and ECM production by perivascular fibroblasts, intimal occlusion and 
microvascular destruction (31). Fibroblast activation leads to perivascular 
adventitial expansion, interstitial fibrosis and may contribute to neointima formation 
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(31). Together, these vascular changes increase the severity of Raynaud’s 
vasospasms and the risk of complete vascular blockage in SSc patients (46, 76, 
77). If this occurs in areas fed by few blood vessels, it can cause critical ischemia 
and necrosis. Critical ischemia leads to digital ulceration in 40% and amputation in 
approximately 20% of these patients (76). Even resolution of ischemia is fraught, 
as vascular reperfusion can generate reactive oxygen species that further damage 
tissues (78).  
Adventitial thickening is suspected to constrict vessels and increase the risk 
of critical ischemia in SSc (23, 79, 80). However, there are few primary studies of 
the PA in SSc skin disease. Early histopathology studies were the first step in 
identifying that adventitial thickening may contribute to SSc vasculopathy (79, 81–
83). Only two SSc-related studies have remarked on the PA. One demonstrated 
elevated levels of leukotriene B4 in the serum of patients with pulmonary arterial 
hypertension (PAH) (84). Blocking leukotriene B4 signaling in a rat model of PAH 
curtailed adventitial enlargement and the development of hypertension (84). Using 
a mouse model of activated TGFβ1 receptor signaling in fibroblasts, the second 
study showed that this was sufficient to drive adventitial fibrosis (85). This study 
did not establish the relative contributions of intimal, medial and adventitial 
changes to vascular dysfunction (85). 
More is known about pathologic vascular constriction by the adventitia in 
cardiovascular diseases than in SSc. Signals such as angiotensin II drive 
production of endothelin 1 and reactive oxygen species by the adventitia (86–88). 
  
11 
This molecular combination acts as a potent vasoconstrictor. Reactive oxygen 
species counteracted nitric oxide-mediated dilation, and endothelin 1 strongly 
induced vasoconstriction by vascular smooth muscle cells (87, 89, 90). In models 
of hypertension, post-angioplasty restenosis and transplant vasculopathy the 
adventitia is often the first vascular layer where proliferation occurs (84, 91–96). T 
cells that are activated in the PA during hypertension exacerbate vascular 
dysfunction by producing IL-17A, which drives fibrosis and further contraction (97). 
Collectively, these data support studying adventitial changes to gain a better 
understanding of SSc pathogenesis. 
Perivascular Cuffing in DLE 
Inflammation and large leukocyte infiltrates are a feature of all DLE lesions 
(12, 98). These infiltrates are likely responsible for the tissue destruction and 
resulting sunken, atrophied scars (5). Activated blood endothelial cells promote 
leukocyte infiltration by expressing E-selectin, intercellular adhesion molecule 1 
(ICAM1), vascular cell adhesion molecule 1 (VCAM1) and peripheral lymph node 
addressin (PNAd) (60, 61, 99). Expression of several leukocyte chemoattractants 
including the CXC motif chemokine receptor 3 (CXCR3) ligands CXCL9, 10 and 
11 is increased in DLE lesions (13, 14, 63). Vascular dilation, which reduces the 
speed of blood flow and increases the frequency of rolling and firm adhesion by 
leukocytes, is part of inflammation such as occurs in DLE (100, 101). Collectively, 
these observations point to blood vessels being central to DLE pathology. 
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Once in the skin, leukocytes receive signals directing them to the dermo-
epidermal junction and hair follicles (13, 14, 63, 64). Perivascular cuffing, or the 
dense accumulation of leukocytes around blood vessels, is also common (12, 98). 
Belying this, perivascular cuffing was recently included in updated diagnostic 
criteria for DLE (98). Little is known about perivascular cuffing in DLE. Only one 
study has examined differences in leukocyte infiltrate composition between the 
dermo-epidermal junction and perivascular space (102). These investigators found 
comparable levels of CD4 and CD8 T cells, CD20+ B cells, CD68+ macrophages 
and cells expressing CXCR3 and one of its ligands, CXCL10 in the two locations 
(102). Accumulation of leukocytes in the PA is better studied in other diseases, the 
best known of which is atherosclerosis. 
Leukocytes infiltrating the aortic adventitia were observed as early as 1962 
(103). More recently, organized structures (called tertiary lymphoid structures or 
TLS) resembling secondary lymphoid organs were identified in the adventitia of 
both humans and mice (104, 105). Aortic TLS are a site of local immunological 
priming, likely generating both protective and pathological responses (104, 106, 
107). TLS are supported by networks of specialized fibroblasts similar to those 
found in lymphoid organs (108–111). These fibroblasts produce pro-survival 
cytokines and retentive chemokines, and generate a microenvironment conducive 
to lymphocyte priming (108–111). Current evidence suggests that priming of 
regulatory T cells (Treg) in TLS delays vascular occlusion in a murine model of 
atherosclerosis (104). Later in the disease, it is postulated that Tregs lose control 
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of the TLS and leukocytes appear to enter the media heading for intimal plaques 
(112). This model of the aortic TLS suggested that similarly specialized networks 
of adventitial fibroblasts may contribute to the perivascular cuffing common to DLE 
lesions. 
PA Mesenchymal Cells in SSc and DLE 
Endothelial cells are the most famous constituents of vascular units, but 
many vessels are dominated by mesenchymal cells (71–73, 113). Vascular units 
wrapped by all three layers are surrounded by at least four types: pericytes, 
vascular smooth muscle cells, fibroblasts and MSC (Fig. 1) (114–118). Two of 
these, fibroblasts and MSC, are found in the PA (115–118). These normally sessile 
adult mesenchymal cells derive from motile, ECM-producing embryonic precursors 
(119, 120). In this dissertation, “MSC” refers to cells thought to be capable of self-
renewal and multi-lineage differentiation. “Fibroblast” will refer to cells thought of 
as being more differentiated. Neither of these definitions is set in stone, as the 
abilities of both fibroblasts and MSC to proliferate and differentiate are under 
investigation. When the precise identity of the cell is unclear, “mesenchymal cell” 
encompasses multiple cell types within this lineage.  
Because of their developmental heritage, adult mesenchymal cells are 
commonly conflated with fibroblasts. However, over the past two decades, 
differences among fibroblasts from distinct organs and within the same tissue have 
been discovered (40, 121–129). For example, in lymph nodes there are at least 
seven phenotypically and functionally distinct fibroblast subsets (130–139). Many 
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of these are specialized to support the survival and functions of specific types of 
leukocytes (130–139). Within the skin, many populations of fibroblasts exist 
including papillary and reticular dermal fibroblasts, as well as fibroblasts of the hair 
follicle papilla and hair follicle sheath (40, 74, 125–129, 140). Recent evidence has 
implicated fibroblasts in functions beyond ECM production, such as fighting 
infections, and the pathogenesis of inflammatory diseases and cancers (118, 123, 
141–151). Increasing recognition of mesenchymal cell heterogeneity has sparked 
interest in associating specialized fibroblast states with disease pathologies, and 
therapeutically targeting these cells. 
Potential Roles for PA Mesenchymal Cells in SSc 
Little is known about the PA in SSc skin disease, so there is much to be 
gained from studying changes to its resident mesenchymal cells. Although 
vascular injury is thought to be one of the first triggers of SSc, this has not been 
definitively proven (78, 80, 152, 153). In lSSc patients, vascular dysfunction usually 
long precedes skin fibrosis, but in dSSc patients the two can occur almost 
simultaneously (27). Several animal models of vascular and hypoxic diseases PA 
demonstrated that fibroblasts proliferate and become activated prior to other 
vascular or interstitial cells (91, 92, 94). Regardless of whether the primary injury 
in an SSc patient is vascular or interstitial, PA fibroblasts may sense and respond 
to both cases (113). Consistent with this concept, we previously observed 
expansion of a discrete set of CD90+ PA fibroblasts in the skin of SSc and DLE 
patients (154). 
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In line with the idea of the PA as a site of first responders to injury, reports 
have identified MSC in the adventitia (115, 116, 155). A local niche of precursor 
cells is likely important for repairing injuries (156–160). In humans, these 
adventitial MSC have been described using several markers including CD34+ 
(115, 161). Adventitial CD34+ MSC have been observed in and isolated from 
human skin (117, 154, 162). Murine dermal perivascular MSC have also been 
identified, and these contributed to dermal fibrosis after inflammatory injury (163). 
A deeper understanding of PA fibroblast and MSC activation in SSc may yield 
insights into how this compartment contributes to vascular pathology and fibrosis. 
PA Fibroblast Support of Leukocytes in DLE 
Leukocyte accumulation in the skin is regulated at several levels, including 
survival and retention (69). Within lymphoid organs, mesenchymal lineage cells fill 
both roles. For example, lymph node fibroblastic reticular cells (FRC) form a 
specialized niche to give succor to T cells. FRC produce the chemokines CCL19 
and CCL21 to attract CC motif chemokine receptor 7 (CCR7)+ T cells and dendritic 
cell (DC)s (143, 164–167). Adhesion molecules, including VCAM1 and ICAM1, 
may be important during the early steps of forming a lymphocyte-supporting niche 
but their role in T cell retention in vivo is unclear (168). In vitro, both ICAM1 and 
VCAM1 contribute to fibroblast-T cell adherence. T cell pro-survival cytokines, 
such as IL-7 and IL-15 round out the care that FRC provide (169, 170). Fibroblasts 
in the skin of DLE patients also produce IL-15, likely thanks to tumor necrosis factor 
α (TNF) from infiltrating T cells or other activated leukocytes (13, 171). 
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Requirements for signaling through the TNF receptors vary among FRC in different 
secondary lymphoid organs; splenic FRC require TNF receptor ligands, while 
lymph node FRC do not (172–175). If the perivascular cuffs observed in DLE 
lesions occur in the PA, these activated fibroblasts may form a supportive niche 
for the leukocytes. 
This notion is supported by evidence that lymphoid organ fibroblasts 
develop from perivascular precursors during both embryonic development and 
inflammation (150, 176–183). Leukocytes extravasate specifically through post-
capillary venules, which lack vascular smooth muscle cells (72, 101, 184). Once 
infiltrating leukocytes pass the endothelial cells and pericytes of the intima, they 
come into direct contact with the post-capillary venule PA (72) making this a 
potential hub for local lymphocyte priming. Local priming of T cells by perivascular 
macrophages and dendritic cells in murine contact hypersensitivity is consistent 
with this idea (185). Examining PA fibroblast activation in DLE may shed light on 
how leukocytes accumulate in the inflamed skin of these patients. 
Central Hypothesis and Summary of Results 
The central hypothesis of this study was that human dermal PA fibroblasts 
are distinct from dermal fibroblasts, and adopt unique activation states associated 
with fibrosis in SSc and leukocyte infiltration in DLE. Dermal PA fibroblasts were 
distinguished from surrounding dermal fibroblasts, leukocytes, endothelial cells, 
VSMC and pericytes by expression of CD90 and platelet-derived growth factor 
receptor β (PDGFRβ), lack of CD34, α-smooth muscle actin (SMA), CD45 and 
  
17 
CD31, location adjacent to VSMC marked by SMA and morphology of wrapping 
vascular units in healthy skin (186). Expansion of PA fibroblasts was observed in 
the affected skin of both SSc and DLE patients (186). In DLE, activated PA 
fibroblasts expressed VCAM1, which was associated with dense perivascular T 
cell infiltrates (186). VCAM1 transcript levels were positively correlated with 
CCL19, a chemokine that attracts CCR7+ T cells, and IL-15, a cytokine that 
promotes the survival and activation of T cells (164, 169, 171, 184, 186–188). PA 
fibroblasts in SSc skin adopted a distinct NGFR+VCAM1- activation state, which 
was not observed on dermal fibroblasts. NGFR is commonly used to identify MSC 
(189–191), and NGFR+ PA fibroblasts were observed in close proximity to and 
demonstrated phenotypic overlaps with cells previously identified as MSC (115–
117, 180). Expansion of NGFR-expressing PA fibroblasts was also detected in 
reparative and pathologic scarring, as well as four dermal tumors. Together, these 
data indicate divergence between PA and dermal fibroblasts, and identify discrete 
PA fibroblast activation states associated with inflammation and ECM deposition. 
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CHAPTER TWO: MATERIALS AND METHODS 
Data and portions of the text in this chapter were originally published as: 
Barron, A. M. S., Mantero, J. C., Ho, J. D., Nazari, B., Horback, K. L., Bhawan, J., 
Lafyatis, R., Lam, C., and Browning, J. L. (2019) Perivascular Adventitial Fibroblast 
Specialization Accompanies T Cell Retention in the Inflamed Human Dermis. 
Journal of immunology (Baltimore, Md.: 1950). 202, 56–68. 
Tissue Samples 
Diffuse SSc and DLE biopsies were collected and processed as previously 
defined (154). DLE and chronic spongiform dermatitis biopsies for histology were 
selected by pathologists (JB and JDH) based on histological and clinical 
assessment. DLE samples for RNA analysis were paired biopsies of lesioned and 
non-lesioned skin obtained from 7 patients. All biopsies were collected under 
patient consent and approval of the Boston University Medical Campus 
Institutional Review Board. Demographics and clinical characteristics of the patient 
cohorts from Chapter Three are defined in Table 1, and those for Chapter Four are 
in Table 2. Control human tonsil samples were obtained from Boston University 
Medical Center Pathology and lymph nodes were provided by the Renal Section 
from an unused donor kidney (courtesy of Dr. Ramon Bonegio).  
Skin tissue was obtained from four female MRL/MpJ-Faslpr/J (MRL/lpr) mice 
with inflamed skin lesions, and from two C57BL/6 mice at one, two and four days 
post-incisional wounding (dpw) as described previously (154). Approximately full-
thickness, 1-cm long incisions were made in the shaved mid-dorsal skin using a 
  
19 
scalpel, and the wounds were sealed with Liquid Bandaid. Similar wounds have 
grown over the first two dpw followed by contraction over days 3-10, and are fully 
closed by approximately 9-10 dpw (192). Healthy skin adjacent to the incisional 
wounds was also collected from the mice. Liver tissue was collected from one 
Faslgld.apoE-/- (gld.ApoE) mouse as previously described (193) and two C57BL/6 
control mice. Pancreatic tissue was obtained from four female NOD/ShiLtJ (NOD) 
and two control C57BL/6 mice. All mice were originally from The Jackson 
Laboratory (Bar Harbor, ME), and none of the controls were co-caged or 
littermates of the experimental animals. Histological analyses were conducted on 
all of the tissues described above. All murine tissues were collected with approval 
by the Boston University Medical Campus Institutional Animal Care and Use 
Committee.   
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 RNA analysis  Histology 
Indication H H SSc DLE DLE AD  H SSc CSD DLE 
Source BU GEO BU BU GEO GEO  BU BU BU BU 
N 15 21 65 7 7 13  15 60 17 19 
Age (years)            
Mean (SD) 
46 
(14) ND 
50 
(11) 
42 
(10) ND 
40 
(15)  
39 
(16) 
49 
(10) 
54 
(14) 
51 
(20) 
Range 
23-
63 ND 
22-
83 
24-
55 ND 
16-
81  
20-
63 
22-
76 
19-
73 
22-
84 
Sex            
% female 67% ND 63% 71% 71% ND  31% 65% 41% 89% 
Disease 
duration 
(months) 
           
Mean (SD) ND ND 
19 
(33) 
83 
(64) ND ND  ND 
26 
(39) ND ND 
Range ND ND 
1-
252 
25-
185 ND ND  ND 
0-
252 ND ND 
Systemic 
sclerosis 
characteristics 
           
Diffuse SSc (%) 0% 0% 
100
% 0% 0% 0%  0% 
100
% 0% 0% 
Modified 
Rodnan Skin 
Score 
           
Mean MRSS 
(SD) ND ND 
27 
(9) ND ND ND  ND 
22 
(11) ND ND 
MRSS range ND ND 5-43 ND ND ND  ND 0-48 ND ND 
Mean local 
pinch score (SD) ND ND 
2.2 
(0.7) ND ND ND  ND 
1.8 
(0.8) ND ND 
Local pinch 
score range ND ND 1-3 ND ND ND  ND 0-3 ND ND 
Table 1. Characteristics of healthy, SSc, CSD, AD and DLE patients whose 
biopsies were studied in Chapter Three. 
Samples collected over the past 13 years were included in this study. Due to limited 
material remaining from older biopsies, subsets of patients were used for each 
staining analysis. H, healthy; SSc, systemic sclerosis; DLE, discoid lupus 
erythematosus; AD, atopic dermatitis; CSD, chronic spongiotic dermatitis. ND, not 
determined. 
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 Histology 
Indication H H lSSc dSSc SSc RS HS KS DLE 
Source BU PRESS BU BU PRESS BU BU BU BU 
N 11 12 10 18 13 12 8 8 10 
Age (years)      ND ND ND  
Mean (SD) 
45 
(17) 44 (13) 
51 
(14) 50 (10) 47 (16) ND ND ND 
53 
(20) 
Range 
23-
62 30-71 
31-
69 34-66 25-78 ND ND ND 
27-
84 
Sex      ND ND ND  
% female 65% 42% 80% 65% 46% ND ND ND 65% 
Disease 
duration 
(months) 
         
Mean (SD) ND ND 63 (58) 27 (38) ND ND ND ND ND 
Range ND ND 2-192 6-156 ND ND ND ND ND 
Systemic 
sclerosis 
characteristics 
 
  
  
   
 
Diffuse SSC (%) 0% 0% 0% 100% 100% 0% 0% 0% 0% 
Modified 
Rodnan Skin 
Score 
         
Mean MRSS 
(SD) ND ND 4 (3) 20 (11) 26 (11) ND ND ND ND 
MRSS range ND ND 2-12 0-48 6-43 ND ND ND ND 
Mean local 
pinch score (SD) ND ND 0 (0) 2 (1) 
1.9 
(0.9) ND ND ND ND 
Local pinch 
score range ND ND 0-1 0-3 0-3 ND ND ND ND 
Table 2. Characteristics of healthy, SSc, DLE and reparative and pathologic 
scar patients whose biopsies were studied in Chapter Four. 
Samples collected over the past 13 years were included in this study. Due to limited 
material remaining from older biopsies, subsets of patients were used for each 
staining analysis. H, healthy; SSc, systemic sclerosis; DLE, discoid lupus 
erythematosus; RS, reparative scar; HS, hypertrophic scar; KS, keloid scar. ND, 
not determined. 
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Histology 
All analyses utilized conventional formalin fixed paraffin embedded 
sections. Two-color immunohistochemistry and three-color immunofluorescence 
was performed as described previously (154). Slides were baked at 60°C for 30 
minutes, followed by dewaxing in histoclear for 6 minutes, and rehydration through 
graded ethanol/water baths (100% ethanol, 95% ethanol, 75% ethanol, 50% 
ethanol) and tris-buffered saline, pH 7.4 (TBS: 50 mM Tris base, 150 mM sodium 
chloride, pH to 7.4 with hydrochloric acid). Heat-induced epitope retrieval was 
performed in boiling tris-EDTA buffer, pH 9 (0.1 mM EDTA, 1 mM Tris base) for 20 
minutes using an electric steamer followed by cooling at room temperature for 20 
minutes. Sections were ringed with a pap pen. Endogenous peroxidases and 
phosphatases were blocked with Bloxall (Vector Laboratories) for 20 minutes at 
room temperature. After a brief rinse in TBS with 0.05% Tween-20 (TBST), 
sections were blocked with 2.5% normal horse or goat serum (Vector 
Laboratories). Another brief rinse in TBST was followed by incubation with the 
primary antibody diluted in phosphate-buffered saline, pH 7.4 (PBS: 2.68 mM 
potassium chloride, 0.14 M sodium chloride, 10.14 mM disodium phosphate, 1.76 
mM monopotassium phosphate, pH to 7.4 with hydrochloric acid) with 1% bovine 
serum albumin, heat shock fraction V (Fisher Scientific) for either at 4°C overnight 
or at room temperature for 1-2 hours. Sections were washed in TBST on a rotating 
shaker for 10 minutes at room temperature, followed by incubation with enzyme-
labeled secondary antibody (Vector Laboratories ImmPress horseradish 
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peroxidase (HRP) or alkaline phosphatase (AP) polymer secondary antibodies) for 
30 minutes at room temperature. Following another wash in TBST for 10 minutes 
at room temperature, slides were incubated with the appropriate substrate for 
between 1-10 minutes. For immunohistochemistry, the HRP substrate used was 
AMEC red (Vector Laboratories) and the AP substrate was Hi-Def Blue AP (Enzo 
Life Sciences). Immunofluorescence substrates were tyramide-conjugated CF488, 
CF594 and CF405S (Biotium) diluted to a final concentration of 10 µM in borate 
buffer (100 mM boric acid, pH to 8.5 with sodium hydroxide) with hydrogen 
peroxide added to a final concentration of 0.003% immediately before use. A brief 
TBST rinse was followed by Bloxall quenching of the remaining enzymatic activity 
as before. Additional antigens were detected by repeating the above procedure. 
Slides developed with chromogens were mounted in VectaMount AQ (Vector 
Laboratories), covered and sealed with nail polish; fluorescent slides were 
mounted with either Vectashield Hard Mount, Vectashield Hard Mount with DAPI 
(both from Vector Laboratories) or Fluoroshiled Mounting Medium with DAPI 
(Abcam). 
Antibodies were separately titered for the two modalities. For 
immunofluorescence, an isotype control section was included in each experiment. 
Confocal microscope laser power and photodiode gain were set so that no 
fluorescence was detected from the isotype control. Primary antibodies were rat 
anti-human CD3 (CD3-12; ThermoFisher Scientific, Waltham, MA); rabbit anti-
mouse/human CD3 (polyclonal; Abcam, Cambridge, MA); rabbit anti-human CD20 
  
24 
(EP459Y; Abcam); mouse anti-human CD20 (L26; ThermoFisher Scientific); rabbit 
anti-human CD21 (EP3093; Abcam); mouse anti-human CD31 (mAbs 
C31.3+JC/70A; Novus Biologicals, Littleton, CO); rat anti-mouse CD31 (SZ31; 
Dianova, Hamburg, Germany); mouse anti-human CD34 (QBend10; Dako, 
Carpinteria, CA); rabbit anti-human/mouse CD34 (EP373Y; Abcam); mouse anti-
human CD45RA/RO (mAbs 2B11+PD7/26; Dako); rabbit anti-human CD90 
(EPR3132; Abcam); rat anti-mouse CD90 (IBL-6/23; Abcam); mouse anti-human 
CD90 (7E1B11; Promab, Richmond, CA); mouse anti-human SMA (1A4; Dako); 
rabbit anti-mouse/human SMA (E184; Abcam); goat anti-human VCAM1 
(polyclonal; R&D Systems, Minneapolis, MN); rabbit anti- mouse/human VCAM1 
(EPR5047; Abcam); mouse anti-human PDPN (D2-40; Dako); rat anti-human 
PNAd (MECA79; Santa Cruz Biotechnology, Dallas, TX); rabbit anti-mouse/human 
NGFR (EP1039Y; Abcam); mouse anti-human FDC (CNA.42; Dako); rabbit anti-
mouse/human PDGFRβ (28E1; Cell Signaling Technology, Danvers, MA); mouse 
anti-human NGFR (NGFR5+NTR/912; Novus); rabbit anti-human CD73 
(EPR6114; Abcam); mouse anti-UCHL1 (13C4; Abcam).  
Morphometrics were performed using the FIJI distribution of ImageJ2 (194, 
195). Regions of interest were drawn around distinct vascular units. For measuring 
perivascular areas covered by PA fibroblasts expressing VCAM1 or NGFR in 
immunohistochemically-stained samples, the brown and blue were separated 
using the Color Deconvolution plugin (196). Custom color vectors were created 
using images of single stained slides developed with only brown or blue and 
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imaged under the same conditions as the slides to be analyzed. Positive controls 
were used to set threshold values, and binary images were created. Staining 
above the threshold value within each region of interest was measured. Images 
used in each morphometric analysis were captured at the same time using the 
same microscope and camera settings. 
Antibody Clone Dilution 
Rat anti-human CD3 CD3-12 1:4000 
Rabbit anti-mouse/human CD3 polyclonal 0.2 µg/mL 
Rabbit anti-human CD20 EP459Y 0.6 µg/mL 
Mouse anti-human CD20 L26 Neat 
Rabbit anti-human CD21 EP3093 0.1 µg/mL 
Biotinylated mouse anti-human CD31 C31.3+JC/70A 8.0 µg/mL 
Rat anti-mouse CD31 SZ31 2.0 µg/mL 
Mouse anti-human CD34 QBend10 0.1 µg/mL 
Rabbit anti-mouse/human CD34 EP373Y 5.0 µg/mL 
Mouse anti-human CD45RO/RA 2B11+PD7/26 0.8 µg/mL 
Rabbit anti-human CD90 EPR3132 0.2 µg/mL 
Rat anti-mouse CD90 IBL-6/23 5.0 µg/mL 
Mouse anti-human CD90 7E1B11 1:500 
Mouse anti-human SMA 1A4 2.0 µg/mL 
Rabbit anti-mouse/human SMA E184 2.0 µg/mL 
Goat anti-human VCAM1 Polyclonal 1:1500 
Rabbit anti-mouse/human VCAM1 EPR5047 0.2 µg/mL 
Mouse anti-human PDPN D2-40 Neat 
Rat anti-human PNAd MECA79 1:1000 
Rabbit anti-human/mouse NGFR EP1039Y 2.0 µg/mL 
Mouse anti-human FDC CNA.42 0.5 µg/mL 
Rabbit anti-mouse/human PDGFRβ 28E1 1:200 
Mouse anti-human NGFR NGFR5+NTR/912 0.2 µg/mL 
Rabbit anti-human CD73 EPR6114 1:2000 
Mouse anti-human UCHL1 13C4 1:50000 
Table 3. Antibodies used for histology. 
Gene Expression Data and Analysis 
All microarray data used in this paper is available from the GEO database 
(https://www.ncbi.nlm.nih.gov/geo/). GEO accession numbers for each data set 
are listed below. The microarray gene expression data in this study was obtained 
as either internal or from public GEO databases as follows (n=129): Normal 
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controls in house (n=14) and GEO (n=21, GSE52471, GSE32407, and 
GSE32924), SSc internal (n=65, GSE94340, GSE95065, GSE55036), DLE 
internal (n=7, GSE120809) and GEO (n=7, GSE52471), and atopic dermatitis (AD) 
GEO (n=15, GSE32924) and all used either the Affymetrix array U133A 2.0 or 
U133A Plus 2.0 chips (197–201). Raw array CEL files were processed with the 
“affy” package from the statistical software R studio (version 3.3.2) and normalized 
using the RMA algorithm. Microarray probe sets were mapped using Brainarray, 
version 21.0.0, Entrez mapping 
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF). 
Correction for batch effects was performed by using the COMBAT algorithm part 
of the SVA package (version 3.22.0) (202). Low variation genes were then filtered 
out by selecting genes with a standard deviation greater than 0.3 from the median 
expression across all samples, resulting in 8,575 genes for further analysis. To 
determine the composition of infiltrating immune cells in the tissues of the different 
diseases, we utilized the CIBERSORT algorithm (http://cibersort.stanford.edu/) as 
described by Newman et al (203). CIBERSORT returns the percentage of the RNA 
that can be accounted for by the various subsets and this percentage was 
normalized using the ratio of a pan leukocytic marker (CD45/PTPRC) to GAPDH. 
The final fraction is proportional to the absolute numbers of leukocytic subsets. All 
T and B cell subsets were summed to create total T and B values reflective of the 
biopsy content. 
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Cell Culture 
Primary human neonatal foreskin fibroblasts were derived as previously 
described (204) and grown in Advanced Modified Eagle’s Medium with 5% fetal 
bovine serum, 10 mM HEPES, 2 mM GlutaMAX, 100 U/mL penicillin and 100 U/mL 
streptomycin (all from ThermoFisher Scientific). Cells were used for experiments 
before passage 13. For experiments, 40,000 fibroblasts were plated in 6-well 
plates and equilibrated overnight. Fibroblasts were treated by adding fresh 
complete Advanced Modified Eagle’s Medium (described above) with the 
combination of 10 ng/mL TNFα (R&D Systems, Minneapolis, MN) and 200 U/mL 
IFNγ (Stemcell Technologies, Vancouver, BC, Canada), dimethyl sulfoxide 
(DMSO, Sigma-Millipore, Burlington, MA) to a final concentration of 2 or 4%, 
dimethylformamide (DMF, Sigma-Millipore) to a final concentration of 2% or 1 µm 
retinoic acid (RA, Sigma-Millipore). 
Flow Cytometry 
Cells were harvested for flow cytometry after three days of stimulation. 
Accutase (Biolegend) was used to detach the cells, which were transferred to 96-
well, round-bottom plates (Corning, Corning, NY) for staining. Zombie UV viability 
dye (Biolegend) diluted in PBS or Hank’s Balanced Salt Solution (ThermoFisher 
Scientific) was used to exclude dead cells, followed by staining with the following 
primary labeled antibodies (also see Table 4): anti-NGFR PE-Cy7 (clone ME20.4), 
anti-VCAM APC (clone STA), anti-CD90 APC-Cy7 (clone 5E10), anti-PDPN PE 
(clone NC-08), anti-ICAM1 FITC (clone HA58) and anti-PD-L1 Brilliant Violet 421 
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(clone 29E.2A3) all from Biolegend. Fluorescence-minus-one controls were 
included for the NGFR and VCAM stains. An isotype control sample was also 
included in all experiments. Antibodies were diluted in FACS buffer (1x PBS or 1x 
Hank’s balanced salt solution (no phenol red, calcium or magnesium), 1% bovine 
serum albumin heat shock fraction V and 0.1% sodium azide). All samples were 
run on a BD LSRII (Becton, Dickinson and Company, Franklin Lakes, NJ) using 
450/50 nm filters to collect Brilliant Violet 421 and Zombie UV from the 355 nm and 
405 nm lasers, respectively; 505 nm long-pass and 530/30 nm filters to collect 
FITC from the 488 nm laser; 735 nm long-pass and 780/60 nm filters to collect PE-
Cy7 and a 590/35 nm filter to collect PE from the 561 nm laser; and 735 nm long-
pass and 780/60 nm filters to collect APC-Cy7 and a 670/30 nm filter to collect 
APC from the 633 nm laser. Software compensation and data analysis was 
performed using FlowJo (Becton, Dickinson and Company). 
Statistics 
Analyses were performed using Prism software. Group comparisons used 
Kruskal-Wallis tests followed by post-hoc pairwise Dunn’s multiple comparison 
tests unless noted. Correlations are Spearman analyses with Holm-Sidak adjusted 
P values. In all cases P values <0.05 were considered significant.   
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Antibody Clone Dilution 
Mouse anti-human CD90 APC/Cy7 5E10 0.40 µg/mL 
Rat anti-human Pdpn PE NC-08 0.25 µg/mL 
Mouse anti-human VCAM1 APC STA 0.5 µg/mL 
Mouse anti-human ICAM1 FITC HA58 0.5 µg/mL 
Mouse anti-human NGFR PE/Cy7 ME20.4 0.5 µg/mL 
Mouse anti-human PD-L1 BV421 29E.2A3 0.25 µg/mL 
Mouse IgG1, κ isotype control APC/Cy7 MOPC-21 0.4 µg/mL 
Rat IgG2a, λ isotype control PE B39-4 0.25 µg/mL 
Mouse IgG1, κ isotype control APC MOPC-21 0.5 µg/mL 
Mouse IgG1, κ isotype control FITC MOPC-21 0.5 µg/mL 
Mouse IgG1, κ isotype control PE/Cy7 MOPC-21 0.5 µg/mL 
Mouse IgG2b, κ isotype control BV421 MPC-11 0.25 µg/mL 
Table 4. Antibodies used for flow cytometry. 
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CHAPTER THREE: PERIVASCULAR ADVENTITIAL FIBROBLAST 
SPECIALIZATION ACCOMPANIES T CELL RETENTION IN THE INFLAMED 
HUMAN DERMIS 
Data and portions of the text in this chapter were originally published as: 
Barron, A. M. S., Mantero, J. C., Ho, J. D., Nazari, B., Horback, K. L., Bhawan, J., 
Lafyatis, R., Lam, C., and Browning, J. L. (2019) Perivascular Adventitial Fibroblast 
Specialization Accompanies T Cell Retention in the Inflamed Human Dermis. 
Journal of immunology (Baltimore, Md.: 1950). 202, 56–68. 
Abstract 
Perivascular accumulation of lymphocytes can be a prominent 
histopathologic feature of various human inflammatory skin diseases. Select 
examples include SSc, spongiotic dermatitis and cutaneous lupus. While a large 
body of work has described various aspects of the endothelial and vascular smooth 
muscle layers in these diseases, the outer adventitial compartment is poorly 
explored. The goal of the present study was to characterize perivascular adventitial 
fibroblast states in inflammatory human skin diseases and relate these states to 
perivascular lymphocyte accumulation. In normal skin, adventitial fibroblasts are 
distinguished by CD90 expression and dense perivascular lymphocytic infiltrates 
are uncommon. In SSc, this compartment expands, but lymphocyte infiltrates 
remain sparse. In contrast, perivascular adventitial fibroblast expression of VCAM1 
is upregulated in spongiotic dermatitis and lupus and is associated with a dense 
perivascular T cell infiltrate. VCAM1 expression marks transitioned fibroblasts that 
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show some resemblance to the reticular stromal cells in secondary lymphoid 
organs. Expanded adventitial compartments with perivascular infiltrates similar to 
the human settings were not seen in the inflamed murine dermis. This species 
difference may hinder the dissection of aspects of perivascular adventitial 
pathology. The altered perivascular adventitial compartment and its associated 
reticular network form a niche for lymphocytes and appear to be fundamental in 
the development of an inflammatory pattern. 
Introduction 
Leukocytic infiltrates occur in various patterns in inflammatory skin disease, 
ranging from diffuse collections at the dermoepidermal junction, such as in 
lichenoid interface dermatitis, to densely packed and highly organized perivascular 
structures (205–207). On one end of this spectrum lies classical inflammation-
induced activation of the endothelium and the display of ICAM1 and E/P-selectins 
which especially facilitate leukocyte entry (208). At the other end, chronic 
inflammation results in the emergence of lymphocytic aggregates that organize 
into lymphoid-tissue-like structures called tertiary lymphoid structures (TLS). 
Generally, TLS possess high endothelial venules (HEV) that allow naïve and 
certain memory lymphocyte subsets to emigrate from the blood, segregated T and 
B cell regions and germinal center reactions (209). Within TLS, the reticular stroma 
begins to resemble the fibroblastic reticular cells (FRC) and follicular dendritic cells 
(FDC) in secondary lymphoid organs, presumably facilitating T and B cell 
segregation and function (210). While TLS have been intensely studied, the 
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reticular stromal underpinnings of the more common unorganized perivascular 
infiltrates, originally termed “perivascular cuffs”, remain poorly explored (211).  
The presence of localized infiltrates can be dissected into entrance, 
retention and egress stages. Decades of work has revealed the mechanisms by 
which inflammation triggers increased leukocytic trafficking through post-capillary 
venules. However, in contrast to secondary lymphoid organs, the questions of 
whether retention and egress are active processes in perivascular infiltrates 
remain ill-defined. We have focused on the perivascular adventitia (PA) or tunica 
adventitia compartment in dermal autoimmune disease. The PA is a fibroblast and 
collagen fiber-rich region external to the vascular smooth muscle layer (tunica 
media). Originally designated veiled cells, such adventitial fibroblasts are observed 
surrounding arterioles and terminal arterioles as well as in post-capillary, collecting 
and larger venules (71, 72). Of late the PA has received increasing notice as a 
reservoir of resident progenitor cells; as such, this region is well-poised to sense 
perturbations and initiate repair programs, but can also be a source of pathogenic 
fibroblasts (212–215). PA fibroblasts, as well as resident macrophages/dendritic 
cells and mast cells, are involved in immune surveillance and an active supportive 
vasculature, the vasa vasorum, could serve as a portal for cellular entry into the 
inflamed compartment (216). This may be the case in atherosclerosis, where TLS 
arise within the arterial adventitial compartment (105, 217).  
Stenmark and colleagues have defined a VCAM1+ (vascular cell adhesion 
molecule-1) fibroblast in the PA of hypoxic rat and calf lungs (218, 219). VCAM1 
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is widely known as an inflammation-induced adhesion molecule on endothelial 
cells mediating integrin α4β1 (very late antigen-4, VLA4) and α9β1 positive 
leukocyte trafficking at both the attachment and transmigration levels (220). This 
trafficking system can be utilized by T cells, monocytes, neutrophils and 
eosinophils (221, 222). However, there is substantial expression on non-
endothelial cells (223), including activated fibroblasts (219, 224–226), 
synoviocytes (227, 228), smooth muscle cells (229, 230), pericytes (231), 
astrocytes (232) and epithelial cells (233, 234). In several instances, the non-
endothelial cell expression dominates (235–237). In secondary lymphoid organs 
from both mouse and human, the reticular stromal networks, i.e. FRC and FDC, 
display VCAM1 (238–241). VCAM1+ reticular networks were described in murine 
models of experimentally induced TLS in the thyroid gland and pancreas (242, 
243). The functional relevance of VCAM1-VLA4 interactions in vivo in these non-
endothelial settings remains poorly explored, although roles for lymphocyte 
retention were demonstrated in Peyer’s patch development (244), the spleen 
(245–247), bone marrow (248, 249) and the fibrotic heart (250). VCAM1 
expression in the vasculature has been explored histologically in SSc and DLE 
skin, albeit with limited resolution (251–253). Despite this long history, the 
questions of whether PA fibroblasts express VCAM1 in human inflammatory skin 
diseases, and whether this correlates with perivascular lymphocyte infiltration, 
remain open.  
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In healthy human skin, lymphocytes are described as occupying primarily a 
perivascular region, although few leukocytes are present relative to inflamed skin 
(254). The skin of chronic cutaneous or discoid lupus (DLE) and many chronic 
spongiotic dermatitis (CSD) patients is characterized by substantial perivascular 
and adnexal inflammation (62, 199, 255–257). In contrast to CSD and DLE, 
expanded perivascular regions are accompanied by only a limited monocytic 
infiltrate in the skin of most SSc patients (16). Only in a small subset of SSc 
patients are substantial perivascular lymphocytic infiltrates present. We 
hypothesized that the differing nature of the perivascular infiltrates in SSc, DLE 
and dermatitis reflects the activation state of the reticular stroma in the PA. A 
picture emerges where the perivascular adventitial compartment expands, 
engulfing the entire infiltrated region with lymphocytes being retained within a 
VCAM1+ reticular network. 
Results 
Defining the Perivascular Adventitial Compartment in Normal, SSc and DLE Skin 
We will use the term “vascular unit” to refer to the entire region 
encompassed by the PA compartment including the vascular media and intima. In 
cases where multiple vessels are surrounded by a single PA compartment, all of 
the vessels are defined as being part of one vascular unit. Earlier work indicated 
that dermal PA fibroblasts are CD90+ (Thy1) and CD34- (154, 258–260). We 
combined CD90 with CD34 and SMA staining to reveal CD90+ cells with 
fibroblastic morphology external to both the CD34+ endothelial and the SMA+ 
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medial layers around blood vessels larger than capillaries (diameter ≥8 µm). These 
CD90+ cells form a layer between the media/intima and the CD34+ dermal 
fibroblasts in sections from healthy skin, where the term “dermal fibroblast” is used 
here to designate non-adnexal fibroblasts external to the perivascular layer (Fig. 
2A-B). We define these CD90+SMA-CD34- cells as perivascular adventitial 
fibroblasts. Extensive co-localization of CD90 and the mesenchymal lineage 
marker PDGFRβ validated these cells as fibroblasts (Fig. 3A). Pericytes are 
distinguished from PA fibroblasts by location, within the basement membrane and 
attached to endothelial cells by peg-socket contacts, and by expression of SMA in 
addition to CD90 and PDGFRβ (70, 261). CD34+ bright cells at the edge of the 
vascular unit were also observed and these are potentially MSC (259). Despite 
potential lineage overlaps between adventitial fibroblasts, MSC, smooth muscle 
cells and pericytes, the PA fibroblasts are readily recognized with this staining 
system.  
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Figure 2. Perivascular adventitial fibroblasts express CD90. 
(A) Immunohistochemical staining of human skin biopsies for CD90 (brown) and a 
combination of CD34 and SMA (both blue) to define the vascular media and intimal 
layers. CD90 staining highlights the PA layer. Scale bar is 200  µm. (B) A higher 
magnification view of the boxed vessels in (A) with adventitial (AF) and dermal 
(DF) fibroblasts indicated. Scale bar is 50 µm. (C) H&E stain of a serial section 
showing the equivalent region in (A) with the region shown in (B) boxed. Scale bar 
is 200 µm. (D) Morphometric analysis of the area of CD90 staining in the PA in 
healthy skin (107 vascular units, 5 volunteers), skin from SSc patients (107 
vascular units, 5 patients), and DLE skin lesions (80 vascular units, 5 patients). 
Area refers to the µm2 of CD90+ pixels per vascular unit. ****, p<0.0001; Kruskal-
Wallis followed by post-hoc pairwise Dunn’s multiple comparison tests. 
  
37 
  
Figure 3. PA CD90+, VCAM1+ and PDPN+ cells are PDGFRβ+ fibroblasts. 
(A) Single channel and merged false color images of a DLE lesion biopsy stained 
as indicated with co-localization in the merge in yellow. (B) DLE lesion biopsy co-
stained for VCAM1 PDPN and CD90 showing the extent of co-localization. 
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In the dermis of SSc patients, the CD90+ PA fibroblast layer was expanded 
relative to healthy controls (Fig. 2A-B, D). CD90 expression appeared more 
intense, but we did not attempt to discriminate between increased expression and 
simply a denser packing of fibroblast processes. The outer edge of the PA abuts 
the CD34+CD90- dermal fibroblasts which were readily distinguished in the normal 
dermis, yet in SSc skin, these cells often convert to a CD34-CD90+ cells (154). 
Notably, we found some examples of PA pathology in the absence of this dermal 
CD34-to-CD90 fibroblast transition (Fig. 2A) suggesting that this aspect of the 
perivascular disease can precede the fibroblast activation. In DLE biopsies, PA 
fibroblasts covered more area than in either healthy controls or SSc patients and 
displayed a morphology similar to that seen in the FRC in lymphoid tissues (Fig. 
2A-B, D). We examined CD90 expression in PA compartments in biopsies from 17 
healthy, 61 diffuse SSc and 11 DLE subjects, and the sections chosen for 
morphometric analysis in Fig. 3D were representative. PA fibroblasts were seen 
around vessels with large perivascular leukocytic infiltrates (Fig. 2A-C). We 
conclude that PA fibroblasts expand in SSc and DLE patients, and in DLE the 
expansion was accompanied by dense leukocytic infiltrates. 
VCAM1 Display on Activated Perivascular Adventitial Fibroblasts  
Since VCAM1 is expressed by activated PA fibroblasts in pulmonary 
hypertension, by normal FRC in lymphoid organs and by lymphoid tissue organizer 
cells during lymph node anlage nucleation (210, 218, 219), we hypothesized that 
PA fibroblasts in DLE patients may express this adhesion molecule. Sections co-
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stained for both antibodies and visualized by immunofluorescence showed 
complete overlap (Fig. 4D). No or very limited VCAM1 expression was observed 
in the PA of dermal blood vessels in healthy individuals (8 donors). The healthy 
patient in Fig. 4A exemplified the high end of PA VCAM1 expression and, when 
present, these positive cells cover a small area. VCAM1-expressing PA fibroblasts 
were infrequent and small in SSc biopsies (3/23), and examples of typical VCAM1-
negative and VCAM1+ SSc PA are shown in Fig. 4A. In contrast to SSc, extensive 
reticular networks of VCAM1+ adventitial cells were detected around vessels in 
the skin of all (14/14) DLE patients examined. Morphometric analysis of 
representative sections supported the conclusion that VCAM1+ PA areas were 
greater in DLE patients than in SSc and healthy skin (Fig. 4B). Co-localization of 
VCAM1 with the mesenchymal marker PDGFRβ confirmed that these cells are 
fibroblastic (Fig. 3A). Moreover, many of the VCAM1+ reticular cells also 
expressed CD90 (Fig. 3B). 
VCAM1 is also expressed by a narrow subset of macrophages, e.g. murine 
and human splenic red pulp macrophages and Kupffer cells in the liver sinusoids 
and therefore we searched for VCAM1+ leukocytes in the human skin samples. 
Although fibroblasts were the most frequent VCAM1-expressing cells in DLE, the 
expected endothelial VCAM1 expression was also detected. CD31+ vasculature 
expressing VCAM1 and vessels lacking VCAM1 surrounded by an extensive 
VCAM1+ reticular network were apparent (Fig. 4C). The VCAM1+ cells as 
revealed with either the rabbit or the goat anti-VCAM1 antibodies were distinct from 
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the pan-leukocyte staining using a CD45RO/RA antibody combination, indicating 
that reticular VCAM1+ cells are not hematopoietic (Fig. 4D). Roughly half of the 
DLE biopsies possessed VCAM1+ endothelium. Therefore, VCAM1 display 
identifies a phenotypic change in the dermal PA fibroblasts in DLE.   
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Dermal Perivascular T Cell Infiltrates Localize to VCAM1+ Vascular Adventitia 
We examined the relationship between the presence of an activated PA 
fibroblast, as defined by VCAM1 expression, and perivascular lymphocytic 
Figure 4. VCAM1 expression defined a different state of the perivascular 
adventitia. 
(A) Typical VCAM1 expression (brown) in the PA compartments in healthy, SSc 
and DLE biopsies with a combination of CD34 and SMA (blue). The SSc VCAM1- 
and VCAM1+ panels represent the full range of patterns observed in SSc. Scale 
bar is 50 µm. (B) Morphometric analysis of the area of VCAM1+ vascular adventitia 
in healthy skin (56 vascular units, 3 volunteers), skin from SSc patients (260 
vascular units, 4 patients), and DLE skin lesions (194 vascular units, 3 patients). 
Area refers to the µm2 of VCAM1+ pixels per vascular unit. ****, p<0.0001; Kruskal-
Wallis followed by post-hoc pairwise Dunn’s multiple comparison tests. (C) 
Examples of VCAM1+ (left) and VCAM1- (right) vessels in DLE, VCAM1 (red), 
CD31 (green). (D) Immunofluorescent staining of a human DLE skin lesion for 
VCAM1 (red; left, goat polyclonal, right, rabbit monoclonal antibodies) and a 
combination of CD45RO and RA (cyan). (C-D) Scale bars are 25µm.  
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infiltrates. In general, densely packed perivascular infiltrates were rare in healthy 
and SSc biopsies. Typical VCAM1+ SSc PA regions contained some (~5-15) 
CD3+ T cells while such infiltrates were not seen in VCAM1- compartments. In 
DLE, dense infiltrates were found in adventitial regions containing VCAM1+ 
fibroblasts outside of the CD31+ and SMA+ vascular intima and media (Fig. 5A-
B). We suspected that infiltrating T cells would co-localize with VCAM1+ PA 
fibroblasts. For this and subsequent analyses, we included patients with the 
histologic diagnosis of CSD to determine whether our findings extended to other 
inflammatory diseases with perivascular infiltrates. Immunofluorescent staining for 
VCAM1 and CD3 showed that PA T cell infiltrates were moderate to dense and 
common in all examined (6/6) CSD and (14/14) DLE patients (Fig. 5C). 
Enumeration of the leukocytes in the vascular media and adventitia of all infiltrated 
vessels using hematoxylin and eosin-stained DLE skin sections confirmed that the 
majority of perivascular leukocytes accumulate in the adventitia (Fig. 5D). 
Morphometric analysis confirmed the influx of CD3+ cells in CSD and DLE skin 
with a 10-50 fold increase over healthy and SSc samples (Fig. 5E). T cell infiltrates 
could require a VCAM1+ vessel to gain access, and hence PA reticular VCAM1 
could simply track with endothelial VCAM1. However, as noted above, many 
examples were found of T cell infiltrated PA without VCAM1+ vessels consistent 
with the notion of PA VCAM1 expression tracking with T cell clusters. 
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Figure 5. Dense perivascular T cell 
infiltrates are found within VCAM1+ 
PA fibroblast networks. 
(A) Low power immunofluorescence 
image of DLE skin showing VCAM1+ 
structures (green), CD31/SMA+ blood 
vessels (cyan) and CD45RA+RO 
positive leukocytes (red), “E” marks the 
epidermis. Scale bar is 100 µm. (B) 
Higher magnification of the white boxed 
area from (A). (C) Immunofluorescent 
staining for VCAM1 (green), CD3 (red), 
and SMA (cyan) in representative 
healthy, SSc, CSD and DLE biopsies. 
Scale bars are 25 µm in (B) and (C). (D) 
Counts of perivascular leukocytes in the 
vascular adventitia and media from 
hematoxylin and eosin stained skin 
sections (101 vascular units, 8 DLE 
patients). (E) Morphometric analysis of 
the area of CD3+ T cells in the PA 
compartment in healthy skin (35 vascular 
units, 4 volunteers), SSc (57 vascular 
units, 5 patients), CSD (47 vascular 
units, 5 patients) and DLE skin lesions 
(57 vascular units, 5 patients). Area 
refers to the µm2 of CD3+ pixels per 
vascular unit. (D-E) ****, p<0.0001. (D) 
Wilcoxon test. (E) Kruskal-Wallis 
followed by post-hoc pairwise Dunn’s 
multiple comparison tests. 
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VCAM1 RNA Levels Correlate with T Cell Accumulation 
To independently query the relationship between VCAM1 expression and 
cellular infiltration, we utilized whole skin RNA expression datasets. Since PA 
fibroblasts dominated dermal VCAM1 expression in the histological views, we 
considered VCAM1 RNA levels as a surrogate for activated PA fibroblasts. Using 
publicly available and in-house microarray data from healthy, SSc, atopic 
dermatitis (AD, a subset of spongiotic dermatitis patients) and DLE patient skin 
biopsies, we created a dataset normalized for batch effects. When compared to 
healthy skin and matched non-lesioned DLE skin, VCAM1 RNA levels were 
elevated in biopsies taken from AD, DLE and a subset of SSc samples (Fig. 6A). 
The CIBERSORT algorithm was used to probe the nature of the cellular infiltrates 
in the various settings (203). CIBERSORT returns proportions of various leukocyte 
subsets, but does not reflect changes in the total number of leukocytes in a biopsy. 
Assuming that CD45 expression was proportional to the total leukocyte content 
while GAPDH reflected the total number of cells, we used the CD45/GAPDH ratio 
to normalize the subset fraction into a value that reflected the relative levels of the 
cell subset in the whole tissue. All CIBERSORT T or B cell subsets were summed 
to represent total dermal T and B cells. T cell RNA signatures were higher in 
lesioned tissue from AD and DLE biopsies compared to matched, non-lesioned 
biopsies (Fig. 6B). Although a subset (8%) of SSc patients had elevated T cell 
signals, the overall distribution was similar to the healthy controls. 
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Figure 6. VCAM1 RNA correlates with T cell infiltration, ITGA4, and IL15, 
but not IL7 RNA. 
(A) Relative VCAM1 RNA expression from microarray analyses of whole skin 
biopsies (NL non-lesioned skin, L lesioned skin). (B) Relative total T cell levels 
as determined by CIBERSORT analysis of the whole biopsy transcriptome. 
(C-F) Relationship between the levels of VCAM1 RNA and total T cells as 
determined by CIBERSORT. (G-I) Relationship between the levels of VCAM1 
RNA and ITGA4, IL15 and IL7 RNA as assessed by microarray. (A-B) *, 
p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; Kruskal-Wallis followed by 
post-hoc pairwise Dunn’s multiple comparison tests. 
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Table 5. VCAM1 RNA is positively correlated with CD3G, IL-15 and CCL19 
RNA in SSc, AD and DLE. 
Rho values higher than 0.7 are bolded. 
Gene Patients VCAM1 CIBERSORT T CIBERSORT B 
  rho Adj. p rho Adj. p rho Adj. p 
VCAM1 Control - - 0.49 0.0798 0.22 0.8805 
 SSc - - 0.69 0.0000 0.44 0.0053 
 AD - - 0.49 0.4320 0.03 0.9983 
 DLE - - 0.88 0.0000 0.60 0.0512 
CD3G Control 0.43 0.1724 0.71 0.0001 0.55 0.0243 
 SSc 0.68 0.0000 0.85 0.0000 0.47 0.0026 
 AD 0.79 0.0000 0.68 0.0166 0.23 0.9847 
 DLE 0.81 0.0000 0.90 0.0000 0.69 0.0102 
ITGA4 Control 0.53 0.0228 0.66 0.0009 0.42 0.2467 
 SSc 0.60 0.0000 0.63 0.0000 0.44 0.0059 
 AD 0.71 0.0020 0.71 0.0092 0.16 0.9899 
 DLE 0.85 0.0000 0.89 0.0000 0.71 0.0056 
ICAM1 Control 0.39 0.2836 0.31 0.6894 0.35 0.5377 
 SSc 0.63 0.0000 0.60 0.0000 0.39 0.0256 
 AD 0.82 0.0000 0.38 0.7805 -0.06 0.9983 
 DLE 0.73 0.0010 0.76 0.0016 0.42 0.5087 
SELP Control -0.14 0.9651 0.06 0.9730 0.12 0.9730 
 SSc 0.39 0.0166 0.25 0.3341 0.17 0.7810 
 AD 0.35 0.7805 0.08 0.9958 0.19 0.9872 
 DLE 0.71 0.0018 0.68 0.0102 0.50 0.1817 
IL-7 Control 0.19 0.8949 0.55 0.0225 0.29 0.7411 
 SSc 0.11 0.9562 0.16 0.8491 0.12 0.9562 
 AD 0.37 0.7493 0.53 0.2641 0.04 0.9983 
 DLE 0.02 0.9938 0.11 0.9938 -0.03 0.9938 
IL-15 Control 0.37 0.4056 0.34 0.5583 0.29 0.7407 
 SSc 0.65 0.0000 0.64 0.0000 0.50 0.0006 
 AD 0.79 0.0001 0.61 0.0874 0.23 0.9847 
 DLE 0.79 0.0001 0.85 0.0000 0.61 0.0502 
CCL19 Control 0.48 0.0640 0.25 0.8406 0.22 0.8805 
 SSc 0.60 0.0000 0.71 0.0000 0.52 0.0003 
 AD 0.76 0.0003 0.53 0.2641 0.18 0.9899 
 DLE 0.79 0.0001 0.70 0.0079 0.42 0.5087 
CCL21 Control 0.24 0.8406 0.10 0.9681 0.10 0.9681 
 SSc 0.29 0.1955 0.48 0.0015 0.29 0.2282 
 AD 0.45 0.4320 0.34 0.8820 0.23 0.9847 
 DLE 0.50 0.1487 0.61 0.0502 0.26 0.9129 
CXCL12 Control 0.60 0.0029 0.16 0.9174 0.04 0.9681 
 SSc 0.04 0.9727 -0.05 0.9727 -0.11 0.9562 
 AD 0.36 0.7704 -0.10 0.9983 0.38 0.7805 
 DLE 0.09 0.9938 -0.24 0.9129 -0.19 0.9566 
CXCL13 Control 0.44 0.1555 0.65 0.0011 0.67 0.0005 
 SSc 0.63 0.0000 0.66 0.0000 0.44 0.0059 
 AD 0.26 0.9378 0.41 0.7493 -0.33 0.8960 
 DLE 0.79 0.0001 0.87 0.0000 0.73 0.0036 
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We found VCAM1 and CD3G RNA correlated strongly in all patient groups, 
and this relationship was largely paralleled with the CIBERSORT T cell data (Fig. 
6C-F, Table 5). These data are consistent with the hypothesis that the presence 
of perivascular T cells tracks with PA reticular VCAM1 expression. The T cell levels 
in AD returned by the CIBERSORT algorithm suggested a less pronounced 
infiltrate than we observed histologically in CSD, and this discrepancy probably 
reflects patient heterogeneity in the AD vs CSD cohorts.  
We queried the datasets for genes that tracked with VCAM1 expression and 
found that expression of Integrin-α4 (ITGA4), i.e. a component of the VLA4 ligand 
for VCAM1, correlated well with that of VCAM1 (Fig. 6G, Table 5). Additionally, 
genes potentially related to FRC function, e.g. homeostatic chemokines or T cell 
survival/growth factors, were also elevated. IL-15, a survival factor for effector T 
cells, tracked well with VCAM1 expression whereas IL-7, a survival factor for naïve 
and memory T cells, did not (Fig. 6H-I, Table 5) (238, 262). Homeostatic 
chemokine levels, i.e. CXCL13 and CCL19, also correlated well with the 
maturation of the reticulum to the VCAM1+ state and presence of T and B cells 
(Table 5). The combination of Intercellular adhesion molecule 1 (ICAM1) and 
VCAM1 expression has been used to track mesenchymal lymphoid tissue 
organizer cell differentiation during development and repair (210). VCAM1 and 
ICAM1 RNA were highly correlated in SSc, AD, and DLE; moreover, the correlation 
of VCAM1 or ICAM1 with T and B cell signatures was similar across diseases, 
consistent with the hypothesis of VCAM1+ PA fibroblasts adopting an FRC-like 
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program (Table 5). It is likely that the VCAM1 and ICAM1 correlations are 
specifically related to lymphocyte infiltration, rather than non-specific sequelae of 
inflammation, as another adhesion molecule, P-selectin (SELP), tracked with 
VCAM1 and T and B cell signatures only in DLE and not in AD (Table 5). Together 
our histological and transcriptomic data support the hypothesis that VCAM1+ PA 
fibroblasts specialize to promote perivascular lymphocyte accumulation.  
Perivascular T Cell Accumulation Can Occur in the Absence of PDPN+ PA 
Fibroblasts 
Podoplanin (PDPN) is another molecule commonly used to characterize 
reticular elements and, like VCAM1, PDPN is expressed by FRC in both secondary 
and tertiary lymphoid organs in mice and humans (210) as well as by FDC in 
humans (263). Using either conventional or immunofluorescence methods, 
stromal PDPN was rarely detected in the PA compartment in healthy and SSc 
biopsies, in roughly a third of the CSD and in all DLE biopsies (Fig. 7A). Stromal 
PA PDPN co-localized with PDGFRβ, CD90, and VCAM1, indicating overlap with 
the VCAM1+ PA fibroblast population; although, the expression pattern of these 
four proteins varied per cell which is consistent with recently published single cell 
RNA-Seq data demonstrating considerable heterogeneity among fibroblasts (127, 
264–266) (Fig. 3A-B). All DLE patients had large networks of PA fibroblasts 
expressing both VCAM1 and PDPN, but VCAM1+PDPN- cells were also seen (Fig. 
7B). Thus, at least three cell types or stages are exemplified here: homeostatic 
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CD90+VCAM1-PDPN-, as well as activated CD90+VCAM1+PDPN- and CD90+ 
VCAM1+PDPN+ PA fibroblasts.  
We determined the relationship between PA fibroblast expression of 
VCAM1 or PDPN and the size of the T cell infiltrates. Importantly, VCAM1+PDPN- 
PA regions with dense T cell infiltrates were found in CSD, indicating that PDPN 
expression was not obligatory for the infiltration (Fig. 7C). By morphometric 
analysis, there was a strong positive relationship between the area covered by 
VCAM1+ PA fibroblasts and the size of PA T cell infiltrates, with relatively few T 
cells in the VCAM1- PA in healthy and SSc skin, and increasingly large T cell 
infiltrates in VCAM1+ PA from CSD and DLE patients. The equivalent correlation 
with PDPN area was poor, although vascular units with very high VCAM1 also 
expressed PDPN (Fig. 7D). Because we detected PDPN on many activated 
keratinocytes in addition to fibroblasts and lymphatics in SSc, CSD, and DLE 
lesions, we were unable to use our whole skin biopsy microarray data to analyze 
fibroblast PDPN correlations with lymphocyte signatures. These data indicate that 
perivascular T cells can accumulate regardless of PA fibroblast PDPN expression.  
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Figure 7. Perivascular T cell 
infiltrates occur regardless of PA 
fibroblast PDPN expression. 
(A) Representative examples of 
PDPN staining (brown) in the PA 
compartment in healthy, SSc and 
DLE biopsies with CD34 and SMA 
(both blue). (B) Low- and high-power 
images of a PDPN+ reticular network 
(red) that co-stained with VCAM1 
(green). (C) Contrast between CSD 
and DLE biopsies showing PDPN 
(red), CD3 (cyan), and VCAM1 
(green). In the CSD panels a PDPN+ 
lymphatic vessel is seen below the 
VCAM1+ network. The DLE panels 
have a dilated PDPN+ lymphatic on 
the right side. (D) Correlation of the 
CD3+ area and the corresponding 
VCAM1+ or PDPN+ areas within 
individual vascular units. Red dots 
are both non-lesioned and lesioned 
DLE biopsies while the remainder are 
healthy, SSc and CSD samples. (A-
C) Low-power scale bar in (B) is 100 
µm, all other scale bars are 25 µm. 
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Do VCAM1+ PA Fibroblasts Resemble FRC? 
One defining characteristic of FRC in secondary lymphoid organs is the 
formation and wrapping of collagen matrix-containing fibers called conduits (210). 
We investigated whether VCAM1+ PA fibroblasts ensheath conduits similar to 
FRC. Rodent conduits contain fibrillins 1 and 2, and even elastin fibers (241, 267, 
268). As elastin fibers are coated with microfibrils, we looked for microfibril-
associated proteins in human conduits that can be identified by 
immunohistochemistry in formalin-fixed, paraffin-embedded tissues. We identified 
microfibrillar-associated protein 5 (MFAP5) as a conduit component in human 
spleen, lymph node, and tonsil, and VCAM1+ FRC were found to wrap the 
MFAP5+ conduits (Fig. 8A-C). We postulated that MPAF5 could potentially identify 
fibrils associated with an FRC-like stroma. In the PA, a subset of VCAM1+ 
fibroblasts in both CSD and DLE were frequently in contact with MFAP5+ 
structures, yet the extent of wrapping was incomplete (Fig. 8D-F). FRC in 
secondary lymphoid organs also express SMA and resemble myofibroblasts (238, 
269). In contrast to lymphoid organ FRC, PA fibroblasts in DLE were SMA-, 
indicating a partial transition to FRC status (compare Fig. 8A-C with 8D-F). On this 
basis we conclude that PA fibroblasts may form incomplete conduit-like structures, 
but lack full FRC differentiation status.   
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  Figure 8. VCAM+SMA- PA fibroblasts associated with MFAP5+ fibers. 
(A) Immunofluorescence images of a human lymph node stained for VCAM 
(green), MFAP5 (red), and SMA (cyan). A low-power view is magnified showing 
the approximate co-localization of VCAM1 and MFAP5 as well as MFAP5 and 
SMA. (B-C) High magnification image of VCAM1+ or SMA+ cells with a cross-
sectional intensity analysis of an individual fiber/reticular cell complex. (D-F) 
Identical analysis of a VCAM1+ network in the PA from a DLE biopsy. Cross-
sectional analysis was consistent with fiber wrapping, but SMA was not present. 
(A, D) Low power scale bars are 100 µm, high power scale bars are 25 µm. 
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Is the PA Compartment a “Perivascular Cuff” or a Tertiary Lymphoid Structure? 
It is reasonable to postulate that there is a continuum of events between 
early unorganized perivascular infiltrates and mature TLS with their high 
endothelial venules (HEV), spatially segregated T and B cells and germinal center 
reactions. Peripheral lymph node addressin (PNAd) expression marks the 
transition from flat to high endothelium, i.e. HEV formation. PNAd+ vessels were 
present in all (11/11) DLE biopsies and were rarer in CSD and SSc biopsies (Fig. 
9A). Dense B cell infiltrates were detected in DLE by both histology (11/12 
biopsies) and RNA (Fig. 9B-C). B cells were rare and sparse in most CSD patients 
(5/6 biopsies), although one patient had a single large, dense B cell infiltrate similar 
to DLE lesions. DLE-like B cell infiltrates were also very rare in SSc (Fig. 9C). Since 
PA PDPN staining appeared to track with B cell presence, we sought to determine 
the presence of PDPN+ FDC networks by staining for CD21. In DLE, 7/11 biopsies 
had CD21+ FDC-like networks present (Fig. 9B), and therefore VCAM1+ PDPN+ 
reticular cells may resemble nascent FDC. The presence of CD21+ PA fibroblasts 
correlated with dense B cell infiltrates; however, B cell infiltrates did not precisely 
co-localize with the CD21 staining (Fig 9B). Likewise, many DLE infiltrates lacked 
the segregated T cell zones and B cell follicles characteristic of mature TLS (Fig. 
9D). We conclude that DLE PA compartments are immature TLS structures.    
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Figure 9. Perivascular structures in SSc, 
CSD, and DLE are not mature TLS. 
 (A) Immunohistochemical staining for 
Peripheral lymph node addressin (PNAd, 
brown) and both CD45RA and RO (blue) in 
healthy (7 volunteers), SSc (7 patients), CSD 
(6 patients), and DLE (11 patients). Boxed 
regions from the low-magnification images in 
the top row are shown in the bottom row. Two distinct DLE patients demonstrate 
PNAd conversion of many vessels throughout the dermis. Top row scale bar 200 
µm, bottom row scale bar 25 µm. (B) Staining of serial sections from two unique 
DLE patient biopsies for CD31 (blue) and CD20 (brown, top) or CD21 (brown, 
bottom). Scale bars are 50 µm. (C) Relative total B cell levels as determined by 
CIBERSORT analysis of the whole biopsy transcriptome. **, p<0.01. ****, 
p<0.0001; Kruskal-Wallis followed by post-hoc pairwise Dunn’s multiple 
comparison tests. (D) A DLE lesion biopsy stained for CD20 (red) and CD3 
(green). The boxed area in the low power image (left) is shown at higher 
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magnification (right). Low-power image scale bar 100 µm, high-power scale bar 25 
µm.   
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Comparison of Murine and Human PA Compartments 
The question of how closely the murine dermal PA compartment resembles 
the human counterpart remains poorly explored. Stenmark and colleagues found 
an expanded PA compartment in hypertensive lungs in humans and calves, but 
only a slight expansion in rats and none in mice (270). We examined whether the 
changes in the vascular units in the human inflamed dermis were mimicked in three 
settings: normal mouse skin, an incisional wound and the lesioned skin of lupus-
prone MRL/lpr mice. Thin PDGFRβ+ fibroblastic cell layers were observed 
surrounding vessels in the hypodermis (the sub-dermal fat layer) or fascial layers 
with no evidence of any dermal vessels having an adventitial layer (Fig. 10A-C). 
More pronounced rings were observed in the hypodermis in the incisional wound 
setting at day 4 and in lesioned MRL/lpr skin (Fig. 10A, C). The vessel in Fig. 11C 
in the MRL/lpr hypodermis was the largest example found. The combined staining 
for CD90 and CD31 revealed the lack of CD90+ rings in both the normal murine 
dermis and hypodermis (Fig. 10D). Thin rings of CD90 staining were visible around 
large hypodermal vessels in healing skin four days after an incisional wound, yet 
similar rims were lacking in active MRL/lpr lesions (Fig. 10D). None of the murine 
injured skin sections contained infiltrated CD90+ vascular adventitial networks 
resembling those in the active human DLE lesions.  
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Figure 10. PA compartment in 
mouse skin. 
(A) Low power images of skin 
sections from non-lesioned 
MRL/lpr skin, C57BL/6 skin 4 
days post-incisional wound (Day 
4 Wound), and an MRL/lpr skin 
lesion stained for PDGFRβ 
(brown) and CD31 (blue). (B-C) 
Higher magnification images of 
the indicated regions in (A) 
showing blood vessels in the 
dermis (B) and hypodermis (C). 
(D) A serial section with the PA 
regions from the vessels in (C) 
were stained with CD90 (brown) 
and CD31 (blue). (E) Serial skin 
sections to those in (A) stained 
for H&E. Epidermis is at the top 
of the pictures. Images were 
representative of 4 MRL/lpr mice 
with lesioned skin, two mice 4 
days post-wounding, and two 
healthy mice. (A, E) Scale bars 
are 100 µm. (B-D) Scale bars 
are 25 µm. 
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Perivascular infiltrates resembling human CSD and DLE were not found in 
the murine dermis as ascertained by H&E staining of the tissues (Fig. 10E). Skin 
from C57BL/6 incisional wounds, as well as the non-lesioned and lesioned regions 
of MRL/lpr mice, lacked VCAM1+ adventitial fibroblasts around dermal and 
hypodermal vessels. The rabbit antibody used to detect murine VCAM1 also 
detected human VCAM1, and there the staining patterns overlapped those of a 
second goat anti-human VCAM1 antibody. Murine keratinocytes, hair follicle 
epithelial cells and lymphoid organ FRC were VCAM1 positive and hence we 
consider the antibody staining validated. We conclude that murine dermal blood 
vessels lack PA fibroblasts, while activated murine hypodermal PA fibroblasts, 
unlike human PA fibroblasts, neither express VCAM1 nor retain infiltrating 
leukocytes. 
We examined murine settings where perivascular leukocyte infiltrates have 
previously been described, e.g. TLS in the liver and pancreas (210). Perivascular 
fibroblastic VCAM1+ networks were observed in the pancreas of NOD mice and in 
the livers of gld.ApoE mice (Fig. 11). Serial sections stained for CD3 and CD31 
indicated that T cell infiltrates in the NOD pancreas and gld.ApoE liver are dense 
in areas of perivascular VCAM1+ fibroblasts and much sparser in parenchymal 
areas lacking VCAM1+ fibroblasts. Subsets of murine FRC have been shown by 
FACS analysis to display CD90 (271). Normal vessels in the mouse liver and 
pancreas also lacked a CD90+ PA ring; however, given that murine T cells express 
CD90, we could not determine if these VCAM1+ TLS networks are also CD90+. 
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The caliber of vessels surrounded by perivascular infiltrates in the murine pancreas 
and liver were larger (≥50 µm diameter lumen) than the vessels seen in the murine 
dermis (≤8 µm) or hypodermis (≤50 µm). However, these vessels were also of 
larger caliber than the human dermal vessels around which perivascular infiltrates 
were seen. These data reveal some basic differences in the stromal architecture 
of the perivascular compartment of mouse and human dermal blood vessels.   
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Figure 11. T cells co-localized with VCAM+ perivascular stromal cells in the 
diabetic NOD pancreas and the livers of gld.ApoE mice. 
(A) Immunohistochemical staining for VCAM (brown) and CD31 (blue) in the 
indicated organs. VCAM1+ Kupffer cells are visible in the liver sinusoids. (B) Serial 
sections to those in (A) stained for CD3 (brown) and CD31 (blue). Healthy organs 
were from C57BL/6 mice. All scale bars are 50 µm. 
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Discussion 
We have exploited the varying degrees of dermal leukocytic infiltration in 
SSc, CSD, and DLE to query changes in fibroblast status within the human dermal 
PA compartment. We found multiple fibroblast states based on the protein 
expression of CD90, VCAM1 and PDPN. Normal PA fibroblasts expressed CD90 
with no or very little VCAM1 or PDPN, and the presence of CD90 distinguishes 
these cells from resting non-PA dermal fibroblasts. PA fibroblasts are likely some 
of the CD90-expressing cells detected by FACS and RNA-Seq in normal human 
skin, adipose tissue and the rheumatoid arthritis synovium (259, 265, 266, 272). 
Display of VCAM1 and/or PDPN further identified cells in inflamed PA settings. 
VCAM1+ networks were prominent in CSD and DLE, whereas its display in SSc 
was less frequent and confined to a smaller region. Nonetheless, when present in 
SSc, the VCAM1+ PA compartment had more T cells present. PDPN expression 
represented another level and was prominent in DLE but relatively rare in SSc and 
CSD. Overlaid upon these states was expansion of the PA compartment which 
occurred in all disease settings. SSc was notable in that the CD90+ PA 
compartment was expanded even though the VCAM1 and PDPN activation 
markers were not present. CD90+ and PDPN- reticular structures were also noted 
in the human spleen (269). 
VCAM1 expression by presumably activated PA fibroblasts correlated with 
dense perivascular T cell infiltration across the skin conditions we studied. The 
association between T cell infiltrates and VCAM1 expression was seen both 
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histologically and transcriptionally. RNA for VCAM1 was positively correlated with 
ITGA4, which, along with ITGB1, comprises the VCAM1 binding VLA4 ligand. The 
use of the CIBERSORT algorithm to quantitate relative levels of T cell infiltration 
supported the relationship between VCAM1 expression and T cell presence. PA 
fibroblast VCAM1 may be sufficient to tether T cells, or it could be part of a 
coordinated program necessary for optimal T cell retention. VCAM1 and T cell 
RNA signatures correlated with CCL19 and IL15, which are produced by FRC to 
attract T cells and to promote their survival, suggesting that VCAM1 acts in concert 
with these molecules (262). In agreement, IL-15 is expressed by VCAM1+ stromal 
cells in mouse bone marrow, lymph nodes and spleen (273, 274). While consistent 
with our hypothesis, it needs to be noted that CCL19 and IL-15 can be produced 
by both non-hematopoietic and hematopoietic cells (169, 275). Alternatively, 
VCAM1 could simply be a surrogate for a fibroblast differentiation state wherein 
other molecular entities control retention, or it is linked to the presence of activated 
endothelial cells that are gating lymphocyte entry. PDPN display in DLE but not 
CSD indicated that it was not essential for T cell accumulation. ICAM1 and VCAM1 
RNA expression tracked closely, and we cannot exclude ICAM1 involvement. 
Indeed, a combination of VLA4 and LFA1 inhibition is often employed to efficiently 
block cell adhesion, yet non-endothelial VCAM1 alone can support lymphocyte 
adherence in multiple settings in vitro, e.g. (225, 227, 228, 231). VCAM1 was also 
more important than ICAM1 in vivo for the development of murine models of 
atherosclerosis and dermatitis (276, 277). Since we observed perivascular T cell 
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infiltrates around VCAM1-negative endothelial cells, we favor the view that the 
VCAM1+ PA reticulum is actively supporting retention. We note that it is also 
possible that vascular VCAM1 expression was limited to specific post-capillary 
caliber venules and some sections simply missed these vessels.  
Expansion of the PA compartment appears to be a common pathological 
event. Almost all SSc biopsies had expanded CD90 positive PA compartments; 
yet, this change rarely supported an enhanced lymphocytic infiltrate. While not 
quantitated in this study, these expanded PA compartments in SSc and DLE 
appeared to encompass multiple small blood vessels at a density not seen in 
normal tissue, perhaps suggestive of neoangiogenesis. It has been suggested that 
angiogenesis occurs early in the disease course in SSc (278). A similar expansion 
of perivascular CD90+ fibroblasts was previously described in human invasive 
melanoma biopsies (279). Unlike in SSc, cancer-associated fibroblasts in 
metastatic melanoma and other tumors frequently express VCAM1 and can 
promote leukocyte infiltration (150, 279–284). Expansion of the CD90+ PA 
networks suggests simple growth of preexisting PA fibroblasts, primarily since 
activation markers were not usually present in expanded SSc regions. In support 
of this idea, FRC networks can expand by direct proliferation during reactive events 
(210). Alternatively, expanded PA reticular networks could derive from local 
perivascular MSC, vascular smooth muscle cells or pericytes. Lymphoid FRC and 
FDC cells have been described as originating from various perivascular cells, e.g. 
pericytes or local adipose associated MSC (181, 285, 286).  
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PA fibroblast VCAM1 expression fits with the theme of inflammation 
recapitulating ontogeny as articulated previously (287, 288). In lymphoid organ 
development VCAM1 display on stromal lymphoid tissue organizer cells 
represents an early differentiation event and is maintained on mature FRC (210). 
The ability to secrete, assemble and completely wrap collagen containing conduits 
is a hallmark of mature lymphoid fibroblasts (177, 242, 289); however, full conduit 
structures have not been described in human TLS (242). Conduits are largely 
wrapped by VCAM1+SMA+ fibroblasts that produce IL-7 in lymphoid tissues. We 
describe here a novel marker for human lymphoid conduits, MFAP5, and in 
contrast to lymphoid FRC, the MFAP5 expression in the PA compartment in CSD 
and DLE was patchy and incompletely wrapped by VCAM1+SMA- fibroblasts. 
Additionally, VCAM1 RNA did not correlate with IL7 RNA. Therefore, the PA 
fibroblasts in CSD and DLE appear to be in a nascent FRC stage. 
To dissect functional roles for the PA compartment, we sought a murine 
system that could mimic the human vascular DLE lesions. However, we could not 
find evidence of an analogous PA compartment in the mouse dermis. Large 
vessels in the mouse hypodermis have a PA fibroblast ring, but these PA 
fibroblasts neither expressed VCAM1 nor scaffolded perivascular leukocyte 
infiltrates in healing wounds and in MRL/lpr lupus-like skin lesions. When present, 
infiltrates were more akin to the scattered cells seen in human interface dermatitis. 
Our results were limited to an autoimmune model and wound healing, and it is 
possible models more similar to human skin can yet be found. For example, 
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Natsuaki and colleagues observed perivascular dendritic cell-T cell clusters in a 
mouse model of contact hypersensitivity that were essential for the activation of T 
effector cells (185); however, these clusters are rather small by comparison with 
the human setting. Where substantial T cell infiltrates were observed in the NOD 
mouse pancreatic islets and the portal triad in the gld.ApoE liver, there was a 
VCAM1+ reticular network that enmeshed the lymphocytes. It is possible that PA 
activation relies on different progenitors depending on the species and organ site 
as suggested for fibrotic processes (214, 215). In any case, these data caution that 
extrapolation from the study of small to midsized perivascular events in the mouse 
to the parallel human settings may be anatomically constrained.  
Using these various skin pathologies to define PA fibroblast transition 
states, we see progression from relatively minor change in SSc to the major 
inflammatory events in CSD and DLE. These PA events may lie on a continuum 
and in this sense parallel observations on peripheral interferon signatures in SSc 
and SLE (290). In the case of DLE, the perivascular infiltrates probably reside 
within the spectrum of tertiary structures. The transition from the T-cell dominant 
vascular lesions in CSD to the TLS-like infiltrates in DLE may reflect a larger 
ensemble event, perhaps depending upon the known inter-connections between 
HEV, FRC program status and dendritic/myeloid cells (291–294). There has been 
much discussion of the potential pathological relevance of TLS in human disease; 
nonetheless, it is likely that the poorly organized perivascular infiltrate is the more 
common event. If these local structures are critical to the generation or retention 
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of activated T or B cells as has been suggested, then the ability to erode these 
structures may be essential to breaking a cycle of chronic inflammatory disease. 
Conversely, their formation in tumors may be a crucial step to facilitate 
immunological responses. The description of the PA reticular elements provided 
here begin to lay the foundation to define the mechanisms for positioning and 
retention of both resident myeloid and lymphocytic cells in the resting state and 
effector cells in disease. Furthermore, it focuses attention on a relatively poorly 
explored anatomical compartment and potentially points towards an 
underappreciated role for VCAM1 in lymphocyte retention in extra-lymphoid 
locales. 
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CHAPTER FOUR: NERVE GROWTH FACTOR RECEPTOR EXPRESSION 
IDENTIFIES AN EXPANDED DERMAL PERIVASCULAR STROMAL CELL IN 
SYSTEMIC SCLEROSIS AND WOUND HEALING 
Abstract 
Vascular abnormalities, including Raynaud’s phenomenon and digital 
ulcers, are considered early events in the pathogenesis of SSc. The PA 
compartment, including CD90+ fibroblasts, enlarges dramatically in SSc, yet the 
phenotype, activation status and driving events for this expansion remain poorly 
characterized. Expansion of PA fibroblasts may be due to activation of MSC, and 
NGFR is induced during proliferation and differentiation of both MSC and epithelial 
stem cells. Compared to healthy skin, NGFR-expressing PA fibroblasts were more 
frequent and expanded in the skin of both limited and diffuse SSc patients. 
NGFR+CD90+ and NGFR-CD90+ adventitial fibroblasts both contributed to the PA 
expansion in SSc. A further subset of NGFR+ cells also displayed CD34 and may 
be PA progenitor cells. Similar expansion of NGFR-expressing PA fibroblasts was 
detected in normal and pathologic scarring, as well as some dermal tumors. The 
expanded NGFR+ PA fibroblast population in SSc was absent in the equivalent 
compartment in the highly infiltrated discoid lupus lesions. These observations 
demonstrated that fibroblasts in the SSc PA compartment are not only expanded, 
but are phenotypically altered. 
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Introduction 
Early studies consistently described alterations to the intima and adventitia 
of small arteries in SSc patients (79, 81, 82, 295), which culminated in LeRoy’s 
1975 proposal of the vascular hypothesis (296). Under this hypothesis adventitial 
thickening and myeloid infiltrates cause the loss of smaller vessels in the plexus, 
drive intimal pathology (296) and increase the risk of critical digital ischemia (23, 
297). Although the vascular hypothesis was proposed over 40 years ago, most of 
the research on vasculopathy in SSc has focused on changes in the intima 
(endothelial/pericyte layer) and media (vascular smooth muscle layer) (298–300). 
In contrast to the intimal/medial regions, the PA compartment has received much 
less attention. Removal of the fibrotic adventitia around digital arteries in the early 
1990’s promoted the healing of ulcers and reduced pain (48, 49), further supporting 
the pathological role of the PA in SSc. Activation of PA fibroblastic cells is common 
to other diseases featuring vascular pathology including hypertension and 
cardiomyopathy (79, 250, 301–303). However, fibroblast expansion is the only PA 
change described in SSc (23).  
PA fibroblasts, originally termed “veil cells” (not to be confused with “veiled 
cells”, which was an early term describing DCs in afferent lymphatics), surround 
the tunica media of arterioles, post-capillary venules and larger blood vessels (71, 
72, 304, 305). Myriad cell types are found in the adventitia, including nerves, 
macrophages, mast cells and MSC (213, 306, 307). As the outer-most vascular 
layer, the adventitia senses and responds to changes in both the vasculature 
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(inside-out signaling) and surrounding tissue (outside-in signaling) (303). In 
several diseases such as hypertension, atherosclerosis and transplant 
vasculopathy, PA fibroblasts initiate or perpetuate inflammation by recruiting and 
retaining leukocytes in the adventitia (308–310). Activation of PA fibroblasts and 
MSC may be early events after vascular injury that contribute to vascular occlusion 
through neointimal formation and medial hyperplasia (92, 311–314). Mounting 
evidence indicates that the perivascular space is home to at least one, and 
possibly several, types of mesenchymal progenitors or MSC (213, 315, 316); these 
MSC can differentiate into a variety of fibroblastic cells ranging from follicular 
dendritic cells (FDC) to vascular smooth muscle cells (VSMC) to adipocytes (177, 
181, 317–320). Substantial work has shown that perivascular MSC make 
significant contributions to parenchymal fibrosis across organs (321, 322). 
Together, these features implicate the adventitia in both vascular and parenchymal 
remodeling during inflammation and fibrosis. 
Several perivascular and non-perivascular mesenchymal cells express the 
p75 low-affinity nerve growth factor receptor/CD271/p75NTR (NGFR). PA and 
pericyte-like cells expressing NGFR have been noted in several human organs 
including the skin (323–327). MSC from many of these same organs express 
NGFR (190, 328). Pericyte expression of NGFR increases during ischemia in the 
eye and heart (329, 330). NGFR marks murine perivascular ADAM12+ MSC that 
are responsible for skin and heart fibrosis (331). NGFR-expressing PA fibroblasts 
also expand in several diseases, including rheumatoid arthritis, primary and 
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metastatic tumors in the bone marrow, muscular dystrophy and multiple sclerosis 
(325, 332–334). In a study of muscular dystrophy patients, perivascular fibrosis 
was the only pathological measure examined that correlated with disease severity 
(335, 336). Human and rodent hepatic stellate cells expressing NGFR localize to, 
and increase in, areas of fibrosis and regeneration (337–339). A marked increase 
in NGFR+ cells occurs in the skin of patients with desmoplastic melanoma and 
scars (327, 340). Despite these connections between perivascular fibroblastic 
cells, NGFR and extracellular matrix deposition no studies have linked these 
observations with cutaneous SSc. 
Previously, we showed that CD90+CD34- PA fibroblasts expand in the skin 
of patients with SSc and DLE (154, 186). In DLE, the fibroblasts were clearly 
activated, indicated by expression of VCAM1, and appeared to support 
lymphocytic retention. Dense PA lymphocyte infiltrates are common in the skin of 
DLE patients (255, 341, 342). In SSc, we could not determine whether the PA 
fibroblasts were different or the normal cells simply occupied a larger area. This 
less differentiated state is consistent with sparse myeloid infiltrates in the PA of 
SSc skin (16). In this study, we sought to identify an alteration in PA fibroblasts 
that would distinguish the enlarged PA in SSc from those in healthy and DLE skin. 
Our hypothesis was that PA expansion in the absence of large infiltrates indicated 
a PA fibroblast activation state distinct from the VCAM1+ PA stroma we previously 
described. Here we describe an increase in frequency and area covered by NGFR-
expressing PA fibroblastic cells in SSc, wound healing and fibromas. 
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Results 
Rare Perivascular Cells Expressing NGFR in Healthy Human Skin are More 
Frequent and Cover Greater Area in SSc 
Expression of NGFR in healthy human skin has been previously described 
in nerve bundles (both Schwann cells and neurons), eccrine gland epithelium, 
transit amplifying epithelial stem cell populations and around blood vessels (323, 
324, 327, 343). Using immunohistochemistry, we confirmed the prior observations 
(Figure 12). Consistent with published data (323), we observed two patterns of 
perivascular NGFR expression in healthy human skin. Around larger vessels, cells 
expressing NGFR surrounded the vessel and were outside of the vascular media, 
indicating an adventitial localization (Fig. 12D). Capillary endothelial cells 
expressing CD31 were directly wrapped by NGFR-expressing cells consistent with 
pericytes (Fig. 12E). In these healthy skin samples, vascular units never had both 
pericyte- and adventitial-like NGFR+ layers. These patterns of perivascular NGFR 
expression were similar to our previously published CD90 staining (154, 186, 344), 
although perivascular NGFR was seen much less frequently than CD90 in healthy 
human skin.  
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Figure 12. NGFR expression in healthy human skin. 
(A) Immunohistochemical staining of a healthy human skin biopsy for NGFR 
(brown) and CD31 (blue) to define vasculature. Epidermis is at the top of the 
frame. Boxed and lettered areas correspond to higher magnification images 
shown in the following frames. (B) A higher magnification view of the boxed hair 
follicle (HF) and nerve (N). (C) Eccrine gland (EG) epithelium. (D) Rare NGFR+ 
perivascular adventitia (Ad) adjacent to a nerve (N). (E) The abluminal surface of 
a capillary (blue) wrapped by a pericyte (P) expressing NGFR. Scale bars are 
150 µm (A) and 50 µm (B-E). 
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Previously we determined that CD90+ fibroblasts in the PA expand in the 
affected skin of SSc and DLE patients (154, 186). We hypothesized that this 
enlarged CD90+ population would also display NGFR in SSc and DLE. 
Immunohistochemistry demonstrated that the area per vascular unit covered by 
NGFR+ cells is larger in the skin of limited cutaneous SSc (lSSc, median 156 
pixels, 95% CI 74-411, range 0-297994) and diffuse cutaneous SSc (dSSc, median 
112 pixels, 95% CI 37-393, range 0-173462) than DLE (median 0 pixels, 95% CI 
0-2, range 0-13675) and healthy (median 0 pixels, 95% CI 0-0 pixels, range 0-
26936) patients as scored by two researchers (Fig. 13A-E). Although perivascular 
NGFR+ cells cover more area in the skin of patients from lSSc, dSSc and DLE, 
the median area covered by these cells was approximately two orders of 
magnitude larger in both SSc groups than in DLE patients (Fig.13E). Unlike CD90, 
perivascular NGFR expression was not observed in dermal fibroblasts in SSc and 
DLE patients (Fig. 13B-D)(154). The proportion of vessels surrounded by NGFR+ 
cells was also higher in both lSSc (median 33% of vessels, 95% CI 24-49%, range 
24-54%) and dSSc (median 26% of vessels, 95% CI 16-36%, range 1-46%) 
compared to healthy (median 3% of vessels, 95% CI 1-6%, range 0-34%) and DLE 
(median 2% of vessels, 95% CI 0-4%, range 0-4%) skin (Fig. 13F). Although 
expansion of perivascular NGFR+ cells occurs in both SSc and DLE, the 
enlargement in SSc skin is dominant. 
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Figure 13. Perivascular cells expressing NGFR are more frequent and cover 
larger areas in the skin of SSc patients. 
Immunohistochemical staining of human skin biopsies for NGFR (brown) and 
CD31 (blue) to define vasculature. Epidermis is at the top of the frame for all 
images. Boxed areas correspond to higher magnification images shown below. (A) 
Healthy skin, fibrotic forearm skin from an lSSc (B) and a dSSc (C) patient and a 
DLE (D) scalp lesion. In the bottom row, nerves (N), perivascular adventitia (Ad) 
and eccrine glands (EG) are indicated. (E) Morphometric analysis of the area of 
NGFR staining around vessels (excluding obvious nerves) in healthy skin (281 
vascular units, 7 volunteers), skin from lSSc (235 vascular units, 5 patients) and 
dSSc patients (289 vascular units, 5 patients) and DLE skin lesions (285 vascular 
units, 5 patients). Area refers to the number of NGFR+ pixels per vascular unit. 
Thresholds for positive staining were set using internal nerve controls for each 
section. The median NGFR+ perivascular areas in lSSc and dSSc patients are 
larger than those for healthy and DLE patients (both p<0.0001). (F) Proportions of 
vessels with positive perivascular NGFR staining from 15 healthy, 10 lSSc, 15 
dSSc and 6 DLE patients. Positivity was determined as in (E). Both lSSc and dSSc 
skin have higher proportions of NGFR+ vessels than healthy and DLE patients (HC 
vs lSSc, p=0.0011; HC vs dSSc, p=0.0251; DLE vs lSSc, p=0.0008; DLE vs dSSc, 
p=0.011). (A-D) Top scale bar is 200 µm, bottom scale bar is 50 µm. (E-F) Kruskal-
Wallis followed by post-hoc pairwise Dunn’s multiple comparison tests. 
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Human Dermal PA Cells Expressing NGFR are Mesenchymal 
Several mesenchymal populations have been found in vascular units in 
human skin: pericytes, vascular smooth muscle cells, adventitial fibroblasts and 
CD34+ adventitial MSC (186, 345, 346). Around smaller vessels, such as 
arterioles and venules, it can be difficult to distinguish pericytes from adventitial 
cells (347). Cells expressing PDGFRβ, CD90 and NGFR around larger vessels 
lacked SMA and melanoma cell adhesion molecule (MCAM), and were outside of 
the vascular intima and media consistent with PA fibroblasts in healthy, SSc and 
DLE skin (Fig. 14A-E). Both NGFR+CD90+ and NGFR-CD90+ cells contributed to 
the PA expansion around dermal vessels in SSc (Fig. 14B). Nerve bundles abut 
the PA and individual axons terminate there (323, 324), so distinguishing between 
NGFR+ mesenchymal, neuronal and Schwann cells was critical. Schwann cells 
were clearly distinct from PA mesenchymal cells as they lacked PDGFRβ and 
CD90 (Fig. 14A-B). Peripheral nerves were distinguished from PA mesenchymal 
cells and Schwann cells by their expression of ubiquitin carboxyl-terminal esterase 
L1 (UCHL1/PGP9.5) and the absence of PDGFRβ (Fig. 14E, A). Some neurons 
expressed CD90 (Fig. 14B), but there was considerable heterogeneity. Together, 
these data support our hypothesis of expanded NGFR+ PA fibroblasts in SSc skin. 
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Figure 14. Perivascular adventitial NGFR+ cells are mesenchymal. 
Representative images of immunofluorescent staining in skin biopsies from SSc 
patients. (A) NGFR (green) and mesenchymal marker PDGFRβ (red); (B) NGFR 
(green) and PA fibroblast marker CD90 (red); (C) NGFR (red) and SMA (green) 
to highlight the vascular media; (D) NGFR (green) along with intimal marker 
MCAM (red) and CD31 (cyan) to mark vasculature; (E) NGFR (green), basement 
membrane protein laminin (red) and CD31 (cyan); (F) NGFR (red), neuronal 
marker UCHL1 (green) and DAPI (cyan). Ad, adventitia; BV, blood vessel; N, 
nerve bundle; DF, dermal fibroblast; M, perivascular media; I/M, both intima and 
media; BM, basement membrane. All images captured with a 60x objective, scale 
bar is 25 µm. 
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Relationships Between NGFR+ PA Cells and Adventitial MSC 
NGFR has been widely used to purify MSC from several human tissues 
including the skin (189, 190). CD34 marks a PA MSC population in several human 
organs, and similar cells have been observed in human skin (154, 162, 345). Thus, 
we asked whether PA cells expressing NGFR also expressed CD34. Overlap of 
CD34 and NGFR in the PA of larger vessels was not observed in healthy skin (4/4 
biopsies, Fig. 15A), and CD34+ MSC were more common in the PA than cells 
expressing NGFR. Dermal fibroblasts also expressed CD34 in healthy skin, 
consistent with previous publications (154, 162, 348). In SSc (4/4 biopsies), rare 
co-localization of CD34 and NGFR could be seen on adventitial cells around larger 
vessels (Fig. 15A). However, it was more common to see outer CD34+ NGFR- and 
inner CD34- NGFR+ adventitial layers (Fig. 15A). Both CD34+ PA and NGFR+ 
dermal MSC expressed CD73 after isolation (190, 345), and this marker is part of 
the International Society for Cellular Therapy (ISCT) minimal criteria for defining 
MSC (349). However, isolation and culture change mesenchymal cell phenotypes, 
and direct demonstration of in situ co-localization of CD73 with CD34+ or NGFR+ 
cells is lacking. Neither pericyte-like nor PA cells expressed both CD73 and NGFR 
in healthy or SSc skin (Fig. 15B). Instead, adventitial CD73+ cells were consistently 
farther from the intima than PA cells expressing NGFR. Dermal fibroblasts in the 
skin of healthy patients also expressed CD73, which served as an internal positive 
control (Fig. 15B).    
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Figure 15. Relationship between NGFR+ PA cells and PA MSC. 
Representative immunofluorescent images of healthy and SSc skin stained for 
NGFR and the MSC markers CD34 (A) and CD73 (B). (A) No PA cells expressing 
both NGFR and CD34 were observed in healthy skin (left). In fibrotic SSc skin, 
co-localization (yellow) of NGFR and CD34 was visible in the PA of <10% of 
vessels (middle). More than 90% of vessels in SSc skin had NGFR+ layers 
adjacent to CD34+ cells, but closer to the vessel lumen (right). (B) No co-
localization of NGFR and CD73 was observed in healthy skin. In two fibrotic SSc 
biopsies PA NGFR+ layers were adjacent to CD73+ MSC layers, positioned 
closer to the intima. (A-B) All images were captured with a 60x objective and 
scale bars are 25 µm. 
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Perivascular NGFR-Expressing Cells are More Frequent and Occupy Larger 
Areas in Human Reparative and Pathologic Dermal Scarring than Healthy Skin 
One hypothesis is that SSc represents a dysregulation of the normal tissue 
repair process. Human dermal scars display more frequent NGFR expression 
(327) and expansion of CD90+ PA fibroblasts (344) relative to healthy skin. 
However, it is unclear whether the expanded PA fibroblasts in human scars 
express NGFR. IHC demonstrated that NGFR+ perivascular populations covered 
more area per vessel in reparative (RS, 8/8), hypertrophic (HS, 8/8) and keloid 
(KS, 8/8) scars compared to healthy skin (Fig. 16A-F). Median area per vessel 
occupied by cells expressing NGFR in RS (2391 pixels, 95% CI 1283-4526, range 
0-555713), HS (3204 pixels, 95% CI 2274-4427, range 0-744177) and KS (3130 
pixels, 95% CI 3130-6179, range 0-953749) were larger than in healthy skin (0 
pixels, 95% CI 0-1, range 0-13020) (Fig. 16E). In fact, the median perivascular 
area covered by NGFR-expressing cells in both reparative and pathologic scars 
was approximately an order of magnitude larger than in SSc patients (2391 pixels 
for RS, 3204 for HS and 3130 for KS versus 156 for lSSc and 112 for dSSc). 
Vascular units containing NGFR+ cells were also more common in RS (median 
44% of vessels, 95% CI 29-60%, range 29-60%), HS (median 39% of vessels, 
95% CI 34-63%, range 34-63%) and KS (median 39% of vessels, 95% CI 25-81%, 
range 25-81%) than healthy (median 9% of vessels, 95% CI 2-18%, range 2-18%) 
skin (Fig. 16F). These data are consistent with PA fibroblasts responding similarly 
in SSc and during normal and pathologic dermal wound repair. 
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Figure 16. Expansion of perivascular cells expressing NGFR in reparative 
and pathologic scars. 
Immunohistochemical staining of human skin biopsies for NGFR (brown) and 
CD31 (blue) to define vasculature. Epidermis is at the top of the frame for all 
images. Boxed areas correspond to higher magnification images shown below. (A) 
Healthy skin, a reparative scar (RS) (B), a hypertrophic scar (HS) (C) and a keloid 
scar (KS) (D). In the bottom row, nerves (N), perivascular adventitia (Ad) and 
pericytes (P) are indicated. (E) Morphometric analysis of the area of NGFR 
staining around vessels (excluding obvious nerves) in healthy skin (247 vascular 
units, 10 volunteers), RS (286 vascular units, 8 patients), HS (515 vascular units, 
8 patients) and KS (495 vascular units, 8 patients). Area refers to the number of 
NGFR+ pixels per vascular unit. Thresholds for positive staining were set using 
internal nerve controls for each section. The median NGFR+ perivascular areas in 
RS, HS and KS were larger than those for healthy volunteers (all p<0.0001). (F) 
Proportions of vessels with positive perivascular NGFR staining from 5 healthy 
skin biopsies, 5 RS, 5 HS and 5 KS. Positivity was determined as in (E). RS, HS 
and KS all have higher proportions of NGFR+ vessels than healthy skin (HC vs 
RS, p=0.0162; HC vs HS, p=0.0176; HC vs KS, p=0.0385). (E-F) Kruskal-Wallis 
followed by post-hoc pairwise Dunn’s multiple comparison tests. Top scale bar is 
200 µm, bottom scale bar is 50 µm. 
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NGFR Expression in the Hypodermis During Early Wound Healing in Mice 
Given the differences between murine and human skin (350), we next 
examined whether mice would recapitulate the expansion of perivascular NGFR+ 
populations observed in humans. Incisional wounds were made in the dorsal skin 
of female C57BL/6 mice (see methods) and allowed to heal for one, two or four 
days. No perivascular NGFR staining was observed in the healthy skin of 
unwounded mice (Fig. 17A-C). Keratinocytes expressed NGFR in the healthy skin 
of unwounded mice (Fig. 17A), but disappeared from the wound margins (Fig. 17B-
E). Epithelial cells in hair follicles displayed heterogeneous NGFR expression at 
all time points in both healthy and wounded skin (Fig. 17B-D).  
Perivascular NGFR expression was only detected four dpw, and was 
generally restricted to the hypodermal fat adjacent to the wound (Fig. 17B-E). In 
human scars and SSc skin, NGFR-expressing mesenchymal cells were not 
detected anywhere other than the perivascular space (Figs. 13 and 16). This was 
different in murine wounds where, at four dpw, NGFR-expressing fibroblastic cells 
were spread throughout the hypodermis (Fig. 17D-E). Images from serial sections 
stained with Masson’s trichrome are shown below each immunohistochemistry 
image to indicate the wound (Fig. 17F-J). NGFR expression by fibroblastic cells is 
not restricted to the PA during murine wound healing.   
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Figure 17. NGFR+ cells appear in the murine hypodermis 4 days post-
incisional wound in skin adjacent to the wound. 
Serial sections from healthy skin (A, F), and incisional wounds at 1 (B, G), 2 (C, 
H) and 4 (D, I) days-post wounding (dpw), as well as skin distal to the wound at 
4 dpw (E, J) stained for NGFR (brown) and CD31 (blue) (A-E) or Masson’s 
trichrome (blue, collagen; red, muscle and keratin; pink, fibrin; brown/black, 
nuclei) (F-J). Epidermis is at the top of the pictures. Images were representative 
of two C57BL/6 mice per group. E, epidermis; HF, hair follicle; S, scar; Ad, 
perivascular adventitia. Scale bars are 100 µm. 
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Perivascular NGFR Expression is Common in Four Types of Dermal Tumors 
Fibromas and sarcomas represent other conditions where mesenchymal 
proliferation and extracellular matrix deposition occur, and vascular activation is 
common within and around tumors. Previous publications have shown that 
cutaneous neurofibromas frequently express NGFR (323, 351), and we observed 
diffuse NGFR staining in the dermis of all (2/2) cutaneous neurofibroma specimens 
studied (Fig. 18). Similarly, the dermatofibrosarcoma protuberans specimens (2/2) 
we examined had diffuse NGFR expression (Fig. 18). Because of the diffuse 
NGFR expression in neurofibromas and dermatofibrosarcoma protuberans it was 
difficult and beyond the scope of our current study to distinguish between 
perivascular and tumor-associated NGFR. Neither dermatofibromas (2/2) nor 
atypical fibroxanthomas (2/2) had wide-spread NGFR expression in the dermis; 
rather, both of these entities demonstrated perivascular NGFR expression similar 
to our observations in SSc and scars (Fig. 18). These data are consistent with the 
association of perivascular NGFR expression with dermal conditions marked by 
fibroproliferation and extracellular matrix deposition.   
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Figure 18. Patterns of NGFR expression in four dermal tumors. 
Immunohistochemical staining of human skin biopsies for NGFR (brown) and 
CD31 (blue) to define vasculature. Epidermis is at the top of the frame for all 
images. Boxed areas correspond to higher magnification images shown below. 
NF, neurofibroma; DFSP, dermatofibrosarcoma protuberans; DF, 
dermatofibroma; AFX, atypical fibroxanthoma. Top scale bar is 200 µm, bottom 
scale bar is 50 µm. 
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Expanded PA Fibroblasts in SSc and DLE Distinguished by NGFR and VCAM1 
Expression 
Our previous work demonstrated that VCAM1-expressing PA fibroblasts are 
common in DLE skin lesions and rare in the skin of healthy and SSc patients (186). 
We hypothesized that expression of NGFR or VCAM1 is exclusive on PA cells in 
SSc and DLE. PA cells expressing both VCAM1 and NGFR were only seen around 
one vessel of over 80 examined in two SSc and two DLE biopsies. In DLE biopsy 
specimens (2/2), PA fibroblasts were VCAM1+NGFR-, while PA fibroblasts in SSc 
skin were VCAM1-NGFR+ (Fig. 19A). Plotting the perivascular areas of VCAM1 
and NGFR expression demonstrated larger perivascular areas of NGFR+ than 
VCAM1+ in SSc and the converse in DLE (Fig. 19B-C). As previously reported 
(186), NGFR-VCAM1+ PA fibroblasts correlated with perivascular infiltration. 
Vessels surrounded by NGFR+VCAM1- PA fibroblasts lacked perivascular 
infiltrates (Fig. 19A). These data demonstrate nearly exclusive expression of 
NGFR or VCAM1 by PA fibroblasts in SSc or DLE, respectively, and suggest 
activation states associated with distinct vascular pathologies in these two 
diseases.   
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Figure 19. PA fibroblasts expressing NGFR in SSc and VCAM1 in DLE are in 
distinct states. 
Immunofluorescent staining of SSc and DLE skin biopsies for NGFR (green), 
VCAM1 (red) and CD31 with DAPI (both cyan). (A) Representative images of the 
more common VCAM1-NGFR+ (left) and rarer VCAM1+NGFR- PA fibroblasts in 
SSc skin, along with a perivascular infiltrate from DLE skin showing 
VCAM1+NGFR- PA fibroblasts and an adjacent VCAM1-NGFR+ nerve bundle 
(right). (B-C) Measurements of the perivascular areas covered by NGFR+ and 
VCAM1+ cells in SSc (B) and DLE (C). Each pair of dots connected by a line 
represents one vascular unit (20 SSc and 18 DLE vessels from two biopsies of 
each disease). In SSc (B), the perivascular area covered by NGFR is greater than 
that covered by VCAM1. The opposite is true in DLE (C), where VCAM1 covers 
more perivascular area than NGFR. Wilcox matched-pairs signed rank test, 
p<0.0001 for B and C. (A) Scale bar is 25 µm. 
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Polar Solvents Induce NGFR, While the Combination of TNF and IFNγ 
Stimulates VCAM1 Expression by Cultured Primary Human Dermal Fibroblasts 
The nearly exclusive expression of NGFR by PA fibroblasts in SSc and 
healing wounds, and VCAM1 by PA fibroblasts in DLE suggested that different 
stimuli induce the expression of these two proteins by fibroblasts. Stimuli capable 
of inducing NGFR expression by fibroblasts remain partially uncharacterized, but 
include nerve growth factor and TGFβ1 (352–354). Given the proximity of NGFR+ 
PA fibroblasts to perivascular MSC, we next tested the hypothesis that 
differentiation-inducing stimuli DMSO, DMF and RA (355, 356) would induce 
NGFR on primary cultured human dermal fibroblasts. Both DMSO and DMF 
stimulated NGFR expression (Fig. 20; 4% DMSO vs untreated, p<0.0001; 4% 
DMSO vs TNF+IFNγ, p=0.0004; 2% DMF vs untreated and 2% DMF vs TNF+IFNγ, 
p<0.0001). 1 µM RA, the concentration commonly used in leukemia cell 
differentiation in vitro, failed to alter NGFR levels (Fig. 20B; 1 µM RA vs untreated, 
p>0.9999; 4% DMSO vs 1µM RA, p=0.0014; 2% DMF vs 1 µM RA, p<0.0001).  
Prior publications have demonstrated that the combination of TNFα and 
IFNγ induces VCAM1 on human dermal fibroblasts (357), which we reproduced 
(Fig. 20A, C; TNF+IFNγ vs untreated, p<0.0001). As we hypothesized, this 
combination of cytokines failed to induce NGFR on cultured fibroblasts (Fig. 20A-
B; 4% DMSO vs untreated, p=0.3567; 2% DMF vs untreated, p>0.9999; TNF+IFNγ 
vs 4% DMSO, p=0.0242; TNF+IFNγ vs 2% DMF, p=0.0022). The different stimuli 
did not antagonize each other, however, suggesting that the NGFR+ and VCAM1+ 
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states are different but not mutually exclusive (Fig. 20; for NGFR, 4% DMSO vs 
4% DMSO+TNF+IFNγ, p>0.9999; for VCAM1, TNF+IFNγ vs 4% 
DMSO+TNF+IFNγ, p>0.9999). 
In situ, dermal PA fibroblasts express CD90 while MSC are CD34+; either 
or both of these perivascular cells may contribute to the changes in NGFR 
expression seen in SSc (115–117, 186). Levels of CD90 were also measured to 
evaluate the relationship between CD90 and NGFR display on the surface of 
fibroblasts. Cultures of primary human dermal fibroblasts become uniformly 
CD90+ upon passaging in vitro (Fig. 20D-E) (117, 358, 359). Neither 4% DMSO 
(p>0.9999 versus untreated) nor 2% DMF (p=1683 versus untreated), the 
compounds that induced NGFR, reduced the high baseline expression of CD90 
(Fig. 20D-E).  
ICAM1 is another protein that is produced by fibroblasts in response to 
inflammatory stimuli and, in addition to VCAM1, marks differentiating FRC during 
embryonic development (176, 177, 360–363). The combination of TNF and IFNγ 
increased levels of ICAM1 on the surface of cultured fibroblasts (p<0.0001, Fig. 
20D, F), as was previously described (357). Elevation of ICAM1 expression by 
TNF and IFNγ was not antagonized by the addition of either 4 (p>0.9999) or 2% 
DMSO (p>0.9999, Fig. 20F). Nor did 4% DMSO (p=0.1930) or 2% DMF (p=0.5796) 
increase ICAM1 expression by cultured fibroblasts (Fig. 20F). Together, these data 
support our assessment that NGFR and VCAM1 mark distinctly activated PA 
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fibroblasts in SSc and DLE while also indicating that these activation states may 
not be mutually exclusive.   
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Figure 20. Polar solvents induce NGFR expression by primary human dermal 
fibroblasts, whereas the combination of TNF and IFNγ stimulates VCAM1 and 
ICAM1 production without altering CD90. 
Primary human fibroblasts isolated from neonatal foreskin were treated with 
differentiation-inducing stimuli (dimethyl sulfoxide, dimethylformamide and retinoic 
acid) or a combination of TNF and IFNγ. (A) Representative contour plot of 
untreated fibroblasts (black) or fibroblasts treated with 4% DMSO (blue), TNF and 
IFNγ (red) or a mix of cells treated as above and stained with isotype control 
antibodies. Gates were set based on fluorescence-minus-one controls. (B) Median 
fluorescence intensity (MFI) of NGFR expression on primary human fibroblasts 
after three days of treatment with the stimuli listed on the X-axis. (C) The percent 
of primary human fibroblasts positive for VCAM1 as dictated by a fluorescence-
minus-one control (see gates in (A)). (D) Contour plot of ICAM1 and CD90 
expression in the same cells as in (A). (E) CD90 and (F) ICAM1 MFI. Data in (A, 
D) show population-level expression from one biological replicate in (B-C, E-F). 
(B-C, E-F) Each dot is a biological replicate, with data from three experiments 
amalgamated in these graphs. 
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Discussion 
Augmenting our prior observations (154, 186), these data indicate that PA 
enlargement in SSc includes activation or differentiation marked by NGFR 
expression. Expanded, NGFR+ PA cells in SSc expressed the mesenchymal 
markers PDGFRβ and CD90, but lacked SMA and MCAM. Although neurons also 
display CD90, NGFR+ PA cells lacked the peripheral nerve marker UCHL1 (364). 
One interpretation of these data is that CD90+ PA fibroblasts turn on NGFR in SSc; 
this was demonstrated to be feasible in vitro as untreated primary human dermal 
fibroblasts express CD90, and DMSO and DMF induced NGFR without altering 
CD90 expression. However, without in vivo lineage tracing data we cannot formally 
exclude the possibility of phenotypic conversion by other perivascular residents 
such as Schwann cells or nerves. For decades it was assumed that activated 
fibroblasts drove PA enlargement in SSc skin (81, 82, 295, 296), but our study is 
the first to provide direct support for this hypothesis.  
An alternative hypothesis is that NGFR expression is enhanced in 
proliferating or differentiating MSC. NGFR identifies MSC in several human 
settings (189–191). The presence of rare, perivascular NGFR+ cells in healthy 
skin, and the increased frequency and area covered by NGFR+ PA cells in SSc is 
consistent with a proliferating MSC (323, 326). Vascular units are a potential 
source of MSC (114, 216, 321), and PA MSC have been identified in both humans 
and mice by a variety of proteins including CD34 and CD73 (115, 117, 180). Our 
results suggest a potential PA MSC differentiation sequence in SSc based on 
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phenotype and relative location. CD34+CD73+NGFR- outer PA MSC-like cells 
may give rise to CD34+NGFR+ or NGFR+CD90+ transit amplifying MSC through 
asymmetric division (Fig. 21). These cells may then differentiate into NGFR-
CD90+ PA fibroblasts (Fig. 21). This proposed progression is similar to other 
progenitor differentiation programs. Quiescent basal epithelial stem cells lack 
expression of NGFR, but turn it on while in the transit amplifying state. NGFR on 
transit amplifying cells inhibits differentiation in favor of proliferation, and it is lost 
during differentiation in the suprabasal transition (343, 365). Similar results have 
been observed for myoblasts, which express NGFR prior to differentiation and lose 
it upon joining a myotube (366–369), and MSC (370). The induction of NGFR on 
fibroblasts by differentiation-inducing polar compounds (355, 356, 371) is 
consistent with PA MSC activation. PA MSC receiving chronic repair signals or 
stuck in an intermediate differentiation state in SSc, could be an alternative 
explanation for the expanded NGFR+ PA population.   
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Figure 21. Model of PA mesenchymal cell phenotypes and layers observed 
in affected SSc skin. 
The diagram shows an expanded view of part of the PA with the surrounding 
dermis (left) and the tunica media comprised of VSMC (right). Red cells at the outer 
rim of the PA represent the previously described CD73+CD34+ MSC. To the right 
are CD73-CD34+NGFR+ (green), CD34-NGFR+CD90+ (yellow) and NGFR-
CD90+ (blue) PA mesenchymal cells. For clarity, the most commonly detected 
phenotypes are shown, but gradients in the expression of CD34, NGFR and CD90 
were also observed as denoted by the triangles and diamond above the PA cells. 
The highest expression is indicated by the widest point of the shape. 
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Parallel growth of PA NGFR in reparative and pathologic scars, and in 
dermal fibromas, suggest that this vascular change is fundamental to settings of 
fibroblast proliferation and extracellular matrix deposition. This observation places 
SSc, scars and fibromas alongside multiple sclerosis, muscular dystrophy and 
arthritis (332, 334, 372). Proliferating, NGFR+ PA mesenchymal cells may be 
associated with “central vein sign” fibrosis in multiple sclerosis patients (372–374). 
NGFR-expressing cells in arthritic joints were specialized for attracting myeloid 
cells, and may be similar to the recently identified synovial perivascular CD90+ 
stromal cells ((123, 334), K. Slowikowski and K. Wei personal communications). If 
dermal NGFR+CD90+ PA fibroblasts resemble those in arthritis, they may attract 
the monocyte-rich perivascular infiltrates in SSc skin (16). Macrophage activation 
associates with endomysial fibrosis in human muscular dystrophy patients (375). 
In the murine mdx model of muscular dystrophy, infiltrating CCR2+ macrophages 
produce TGFβ and injured myofibers secrete PDGF-AA to induce perivascular 
fibroblast proliferation and fibrosis (39, 376). Serum CCL2 levels are increased in 
SSc patients, and fibroblasts are a substantial source (18, 377–379) suggesting a 
similar macrophage- and fibroblast-driven repair response may occur in the SSc 
PA.  
Discrete expression of NGFR on expanded PA fibroblasts in SSc, and of 
VCAM1 in DLE is suggestive of cells with distinct functions. This interpretation is 
reinforced by the association of VCAM1+ PA fibroblasts with large perivascular 
lymphocyte infiltrates, and the scarcity of leukocytes in NGFR-expressing PA. We 
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previously proposed that PA fibroblasts in healthy, SSc, dermatitis and DLE skin 
existed on a continuum of activation or differentiation states (186). Our most recent 
data suggest that rather than existing on a continuum, the NGFR state in SSc may 
represent a differentiation pathway separate from that marked by VCAM1. The 
VCAM1+ state likely lies on the “inflammation recapitulates ontogeny” spectrum 
with mature TLS at the far end (141, 183, 380, 381). Placing the NGFR+ PA state 
into a similar differentiation scheme will require further study. Delineating the 
differences between these states will be aided by the growth of single-cell RNA 
sequencing data (145, 382–387), and our phenotypic definitions could serve as a 
touchstone for these analyses. Building on our previous study, these data 
demonstrate that human dermal PA fibroblasts can adopt separate activation 
states that correlate with discrete vascular alterations in SSc and DLE. 
PA fibroblast-specific functions of NGFR await investigation. Other groups 
have, however, demonstrated roles for NGFR in dermal fibroblasts and other 
mesenchymal cells. Nerve growth factor (NGF), an NGFR ligand, is expressed in 
human scars and produced by cultured dermal fibroblasts. Fibroblasts express the 
high-affinity neurotrophic receptor tyrosine kinase 1 (NTRK1/TrkA), which 
responded to nerve growth factor (NGF) by inducing TGFβ secretion, migration 
and collagen gel contraction (352–354). Hepatic stellate cells make similar use of 
the neurotrophin system, where NGFR is important for myofibroblast activation, 
hepatocyte growth factor production and liver regeneration (388, 389). Whole-
mouse NGFR knockout results in embryonically lethal vasculopathy and 
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neuropathy (390), but the critical NGFR-expressing vascular compartment and 
ligands await identification. Binding of pro-NGF to NGFR on pericytes in murine 
models of diabetic retinopathy and during recovery from myocardial infarction 
causes microvascular dysfunction and ischemia (329, 330, 391), while mature 
NGF has the opposite effect (392). NGFR is a promiscuous receptor with many 
potential signaling outcomes that are determined by the receptors with which it 
pairs and the ligands to which it binds (393). If NGFR expression by PA fibroblasts 
contributes to either vascular constriction or dermal fibrosis in SSc, parsing ways 
to manipulate this complex system may yield therapeutic benefits.  
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CHAPTER FIVE: CONCLUDING REMARKS 
Summary of Results and Integration with the Literature 
These studies demonstrated that dermal PA fibroblasts expanded in both 
DLE and SSc, and adopted distinct activation or differentiation states associated 
with discrete vascular alterations (Fig. 22). Expression of VCAM1 was most 
common in DLE and dermatitis, and correlated with dense perivascular T cell 
infiltrates. Thickening of the PA in the absence of large infiltrates was the norm in 
SSc, where fibroblasts expressed NGFR. In healthy human skin, PA fibroblasts 
were phenotypically distinct from dermal fibroblasts, suggesting cells specialized 
to perform separate tasks. Modifying fibroblasts by blocking activating signals or 
selectively depleting altered cells is being tested as a therapeutic avenue for both 
inflammatory and fibrotic diseases (8, 141, 143, 145, 148, 394), and these studies 
support the involvement of PA fibroblasts in SSc and DLE pathology. 
Neither VCAM1+ PA fibroblasts nor large perivascular T cell cuffs were 
observed in skin lesions from MRL/lpr mice, which are considered a model for 
cutaneous lupus. In other murine models of inflammatory diseases, non-obese 
diabetic (NOD) and gld.ApoE, fibroblasts expressing VCAM1 enmeshed dense T 
cell infiltrates around large vessels in the pancreas and liver. PA fibroblasts 
expressing NGFR were observed around large vessels in the murine hypodermis 
during wound healing, but, consistent with a previous report (163), mesenchymal 
cells expressing NGFR extended through the skin unlike humans where it was 
restricted to vascular units. Collectively, these data demonstrate that PA fibroblast 
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activation is a common feature of human skin diseases, and suggest that the 
activation state may influence the observed vascular pathology.   
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Figure 22. Proposed model of PA fibroblast activation states in DLE and 
SSc. 
PA fibroblasts in healthy skin are CD90+VCAM1-NGFR- and form a thin layer—
one to a few cells thick—within the outer layer of vascular units. In SSc, healing 
wounds and dermal fibromas, PA fibroblasts expand and express NGFR (left 
arrow). Although the PA grows in these settings, the activation of PA fibroblasts 
is not accompanied by dense lymphocyte infiltrates. The physiologically-relevant 
activating stimuli that trigger(s) NGFR expression is currently unknown, but the 
induction of NGFR in cultured fibroblasts by differentiation-inducing polar 
compounds suggests activation and elaboration of perivascular MSC. Contrast 
this with the PA fibroblast expansion and activation in DLE and dermatitis (right 
arrow). Conversion to a VCAM1+ state in these inflammatory diseases may 
promote the perivascular accumulation of dense T cell infiltrates. Initiating stimuli 
for this conversion have not been definitively proven, but in vitro stimuli that 
induce VCAM1 on primary human fibroblasts include combinations of TNF with 
IFNγ, IL-4 or IL-13. 
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Mesenchymal Cell Heterogeneity and PA Fibroblast Functions in Healthy Skin 
These studies distinguish dermal PA fibroblasts from other fibroblast 
populations in the human skin. This distinction adds to the field of dermal fibroblast 
heterogeneity, which has existed for at least 40 years. Dermal fibroblast lines 
isolated from a single skin biopsy displayed variable rates of homeostatic and 
prostaglandin E2-stimulated cell division, discrete rates and methods of 
metabolizing testosterone, as well as discrepancies between removal of the N-
terminal propeptide that were stable across several passages in vitro (395–398). 
Contractile “myofibroblasts” that appeared during wound healing and disappeared 
from the mature scar were an early instance of a dermal fibroblast activation state 
(399, 400). Researchers also discovered two discrete populations around the hair 
follicles, dermal papilla and follicular sheath fibroblasts (401, 402). Recent findings 
further illuminated dermal fibroblast complexity by identifying temporal shifts in 
dermal fibroblast populations during development that contribute to neonatal 
regeneration as well as postnatal scarring and dermal fibrosis, but also indicate 
limitations in comparing murine and human dermal fibroblast subsets (40, 125–
127, 129, 163, 403, 404). Despite the rich literature covering dermal fibroblast 
heterogeneity, PA fibroblasts in human skin have received little attention. 
The evidence that PA fibroblasts in healthy human skin are phenotypically 
distinct from reticular dermal fibroblasts suggests that these populations may have 
unique functions. The functions of healthy dermal PA fibroblasts were not 
examined, but animal models provide suggestions. As members of the vascular 
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unit, PA fibroblasts participate in controlling vascular tone. Aortic adventitial 
fibroblasts express the angiotensin II receptor 1, and respond to angiotensin II by 
proliferating and producing the vasoconstrictor peptide endothelin 1 (86, 88). 
Endothelin 1 increases vascular smooth muscle cell contraction and nitric oxide 
release by endothelial cells with the net effect usually being vasoconstriction (405). 
Angiotensin II-driven endothelin 1 production by PA fibroblasts depends upon 
NADPH oxidase, which also produces reactive oxygen species that can counteract 
nitric oxide-mediated vasodilation (87, 89). Thus, PA fibroblasts in healthy human 
skin may be specialized to regulate vascular dilation and contraction. 
Adventitial fibroblasts around hair follicles, sweat and sebaceous glands 
share the PA fibroblast CD90+CD34- phenotype (154, 186, 344) and play critical 
roles in regulating epithelial stem cells. During the earliest stages of hair follicle 
and sweat gland development, matrix metalloproteinases (MMP), such as MMP2, 
produced by adventitial fibroblasts appear to be important for degrading the 
basement membrane and forming tubes and shafts for the invading epithelial cells 
(406, 407). Subsequently, secretion of bone morphogenetic proteins (BMP) by 
mesenchymal cells promotes specification to sweat gland epithelium, while 
mesenchymal production of the BMP inhibitor, noggin, drives hair follicle epithelial 
fate (128, 140, 408, 409). After development, progressive signaling between 
mesenchymal and epithelial cells, including TGFβ and BMP, controls stem cell 
proliferation and differentiation, necessary for hair growth (160, 410). This 
fibroblast-epithelial guided growth and maintenance of adnexal structures may be 
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paralleled by fibroblast-endothelial cell crosstalk during angiogenesis. CD90-
expressing fibroblasts in murine lymph nodes produce vascular endothelial growth 
factor to promote blood vessel growth during inflammation-stimulated enlargement 
(411). Control of vascular maintenance and growth, similar to that exerted on 
epithelial structures, may be another function of PA fibroblasts in healthy skin. 
Another potential role for PA fibroblasts during homeostasis is the 
maintenance of a leukocyte survival niche. An elegant imaging study of human 
skin demonstrated that leukocytes are predominantly perivascular from 60 µm 
below the dermo-epidermal junction to the hypodermis (412). In healthy tissues, 
perivascular leukocytes include mast cells, macrophages, dendritic cells, type 2 
innate lymphoid cells and T cells (412–418). Why these leukocytes accumulate 
around blood vessels in healthy skin is unclear, although CD90-expressing 
perivascular fibroblasts from multiple settings produce chemokines, such as CCL2 
(95, 118, 279). Treg are critical for controlling inflammation and maintaining dermal 
homeostasis, and are found among perivascular T cells in healthy skin (419, 420). 
Fibroblasts within or isolated from healthy organs, including the skin, appear to 
support immunological homeostasis by promoting Treg survival and proliferation, 
and directly suppressing T cell activity in response to IFNγ (358, 415, 421, 422). 
Perhaps homeostatic PA fibroblasts contribute to the balance between 
immunosuppression and inflammation in the skin, similar to fibroblastic cells in 
Peyer’s patches, epididymal visceral adipose tissue and the lungs (146, 151, 413, 
421). 
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Fibroblasts in the healthy reticular dermis are predominantly CD34+CD90- 
but in SSc, healing wounds and pathologic scars many dermal fibroblasts express 
CD90 not CD34 (154, 162, 344, 348), thus resembling healthy PA fibroblasts. In 
SSc, the decrease in CD34 and increase in CD90 transcripts positively correlated 
with cutaneous sclerosis as measured by the MRSS (154). This CD34-to-CD90 
transition occurred as early as 48 hours post-injury, followed by a time-dependent 
reversion to CD34 dominating the reticular dermis (344). Similarly, CD34 
expression disappears from isolated mesenchymal cells within a few passages in 
culture (423, 424), although it is not clear whether this is due to outgrowth of a rare 
cell population or phenotypic conversion. Does this phenotypic convergence 
indicate that dermal fibroblasts in SSc and healing wounds adopt a functional 
program constitutively expressed by PA fibroblasts, or is CD90 a promiscuous 
marker of multiple mesenchymal states? Future studies, including comparative 
single-cell RNA-seq data, may help to unravel this. 
Expansion and Activation of PA Fibroblasts in DLE and Dermatitis 
These studies demonstrated that perivascular cuffs form in the adventitia of 
dermatitis and DLE skin lesions. The interpretation was put forth that activated, 
VCAM1+ PA fibroblasts drove this cuffing by producing a suite of molecules. 
Binding of α4β1 integrin-expressing innate lymphoid cells (ILCs) to VCAM1 on 
mesenchymal cells was necessary for developing the full complement and size of 
Peyer’s patches (168). VCAM1 is also an early marker of differentiating lymph 
node fibroblasts, and is thought to retain organogenesis-driving ILC (176, 177, 
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425–427). Depleting inflamed fibroblasts using either fibroblast activation protein- 
or CCL19-diptheria toxin receptor mice decreased T and B cell accumulation in the 
salivary gland, lung and central nervous system (141, 150, 182). Activated FRC in 
lymph nodes draining an inflamed site are also critical for maintaining elevated T 
cell numbers (143). Yet, macrophages and dendritic cells were sufficient to form 
small, perivascular T cell clusters in a murine model of contact hypersensitivity 
(185). Thus, the question of whether activated, VCAM1-expressing PA fibroblasts 
are necessary for dense T cell accumulation remains open. 
Data from these studies are consistent with the hypothesis that PA fibroblast 
activation precedes T cell accumulation. Although no causal data were presented, 
several published examples support this notion. Initiating events in lymph node 
and Peyer’s patch organogenesis remain murky (428–430), but interactions 
between nerves, endothelial cells, mesenchymal cells and innate lymphoid cells 
(ILC) occur prior to the influx of lymphocytes (165, 176, 177, 360, 425, 426, 431–
434). Fibroblast activation during inflammation in non-lymphoid tissues is also a 
multi-step dialogue between several cell types; however the initial priming can 
occur in the absence of lymphocytes, likely driven by a combination of ILC, myeloid 
cells, epithelial cells and fibroblasts (141, 381). Fibroblasts express pattern 
recognition receptors (435), which are important for the expansion of peritoneal 
fat-associated lymphoid clusters (146), indicating that at least partial inflammatory 
activation could be autocrine. T and B cells do play important roles in initiating the 
development of splenic white pulp (179), and the formation of lymphocyte 
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aggregates in the central nervous system (148), lungs (436, 437) and thyroid (438). 
Further work is necessary to determine whether PA fibroblast activation or T cell 
infiltration occurs first. 
VCAM1 expression can signify one of several fibroblast programs ranging 
from attracting myeloid cells (118, 439, 440) and retaining T cells (186) to fully 
mature FRC (177, 360). This may represent a continuum of activation states. 
Attracting monocytes and macrophages by producing CCL2 is a common feature 
of activated perivascular fibroblasts (95, 118, 123, 279, 440–442). Once in the 
vascular unit, PA fibroblasts activate these myeloid cells by secreting IL-6 (118, 
123, 440, 441, 443). This may parallel the initial perivascular macrophage 
activation described in murine contact hypersensitivity (185). Activated 
macrophages attract DCs and then T cells to blood vessels (185). During this step-
wise dialogue with myeloid cells and lymphocytes, PA fibroblasts may mature 
along a similar path to that proposed for lymphoid organ fibroblasts (177, 428). The 
range of PA fibroblast activation states, from those specialized for macrophage 
accumulation to FRC and FDC in TLS, suggests that the VCAM1+ cells observed 
in dermatitis and DLE may lie on a continuum between these stages. 
The general assumption is that leukocyte aggregates, such as those in DLE 
and dermatitis, promote tissue destruction in inflammatory diseases (109, 110). 
Inhibiting lymphotoxin-β receptor (LTβR) signaling in reactive lymph nodes halts 
immune responses by dampening activated fibroblasts (143). In the murine NOD 
model of type 1 diabetes, disruption of TLS by blocking LTβR signaling inhibits and 
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reverses disease, while overexpressing an LTβR ligand induces diabetes in the 
absence of pancreatic draining lymph nodes (444, 445).  
In certain settings these structures may be protective. Mature TLS occur in 
the aortic adventitia near atherosclerotic plaques in both humans and mice (103–
107, 112, 446), and, conversely, dissolving these TLS by blocking LTβR signaling 
worsens disease (104). However, the net effect of deactivating PA fibroblasts in 
atherosclerosis requires further clarification as there may be a time-dependent 
switch in whether TLS are protective or pathogenic (104, 107, 112). Perivascular 
cuffs, like those in DLE and dermatitis, may serve as efficient sites to activate 
Tregs, foster contact-mediated Treg suppression and generate new Tregs (104, 
415) to control dermal inflammation (419, 420). FRC and fibroblasts stimulated 
with IFNγ can directly suppress T cell activity (358, 447, 448). While these 
mechanisms may initially constrain pathogenic lymphocytes, Treg and fibroblast 
suppression can fail turning the TLS into a site of local immune priming (440). If 
perivascular cuffs in DLE and dermatitis behave similarly, dissolving these 
structures in patients with overly flaring disease may halt or exacerbate local 
inflammatory destruction of the skin. 
Targeting fibroblasts to treat inflammatory diseases and cancers is under 
investigation (449–451). However, fibroblast heterogeneity within an organ makes 
this difficult (123, 129, 145). Pharmacological deactivation or killing of only the 
pathogenic cells while sparing the beneficial ones requires precise knowledge. 
Similarly, time-dependent changes in fibroblast functions within lymphoid 
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aggregates pose the challenge of matching the treatment to the course of the 
disease (112). Boosting immunosuppressive and Treg augmenting fibroblast 
functions early in disease may control pathology, but if patients only present after 
local regulatory mechanisms have irreparably failed, deleting or reprogramming of 
the fibroblasts may be necessary (8, 452).  
Expansion of NGFR+ PA Mesenchymal Cells in SSc, Wound Healing and 
Fibromas 
Physicians and researchers have known for several decades that the 
perivascular adventitia expands in many SSc patients (81, 82, 295), but it is still 
unclear why. This gap in our knowledge contributes to the difficulty physicians face 
in treating SSc-associated vascular complications. Similar adventitial 
enlargements are implicated in several cardiovascular and fibrotic diseases (73, 
216). In the 1990’s, surgeons discovered that stripping the adventitia from arteries 
feeding the ulcerated fingers of SSc patients sped ulcer healing and decreased 
pain (48, 49). Evidence in Chapter Four demonstrated that expansion of 
specialized fibroblasts contributes to perivascular adventitial thickening in SSc. 
This is due, in part, to an amplification of perivascular NGFR-expressing 
mesenchymal cells. Similar elaborations of NGFR+ PA cells were observed in both 
reparative and pathologic human scars, as well as dermal fibromas. Collectively, 
these data suggest that perivascular NGFR expression correlates with fibroblast 
proliferation or ECM remodeling. A better understanding of adventitial thickening 
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and PA fibroblast activation may aid the treatment of digital ulcers and other 
symptoms in SSc patients. 
The presence of scarce, NGFR+ PA mesenchymal cells in the skin of 
healthy patients suggested that these may be activated MSC repairing normal 
wear and tear. MSC have been described in every vascular layer (114, 115, 216, 
321, 453, 454), although some of these populations are under debate (347, 455–
457). NGFR is turned on by transit amplifying epithelial cells, myoblasts, dermal 
papilla fibroblasts and MSC. In all of these, NGFR expression appears to promote 
proliferation and prevent differentiation. Cells in the transit amplifying state are 
proliferating prior to their final differentiation (458). Once transit amplifying cells 
have proliferated to fully fill their niche, they differentiate and lose NGFR 
expression (343, 365, 366, 370, 459). Based on phenotype and location, expanded 
NGFR+ PA were proposed to be transit amplifying cells derived from 
CD34+CD73+ PA MSC (115, 116, 180). This notion fits with the expression of 
NGFR on transit amplifying cells mentioned above, and with the idea that normal 
repair signals are chronically active in SSc patients (460). Induction of NGFR on 
cultured dermal fibroblasts by differentiation-inducing polar compounds further 
supports this hypothesis. However, at least two alternative hypotheses need to be 
considered. 
First, the expanded NGFR+ PA mesenchymal cells in SSc may signify an 
activation state of existing CD90+NGFR- PA fibroblasts. Fibroblastic cells are 
capable of proliferating in vivo and in vitro, indicating they can expand when 
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activated rather than requiring precursor proliferation (141, 411). Although 
fibroblasts are thought of as being more differentiated than MSC, the differentiation 
capabilities and relationships between these cells remain unclear. If NGFR 
represents a PA fibroblast activation state, rather than an MSC transit amplifying 
cell, it may be associated with vascular or dermal repair. NGFR expression by 
murine hepatic stellate cells (also mesenchymal) was necessary for myofibroblast 
differentiation, ECM deposition, hepatocyte proliferation and liver repair (388). 
Fibroblast activation and myofibroblast conversion are thought to be critical drivers 
of fibrosis in SSc. Murine models have implicated the vascular unit as a source of 
fibrosis-driving fibroblasts (114, 321). However, NGFR was restricted to dermal 
vascular units in the SSc biopsies used in this study, and was never observed on 
dermal SMA+ myofibroblasts. While NGFR may indicate a transient PA fibroblast 
activation state, the current data appear more consistent with NGFR marking an 
activated PA MSC in SSc. 
Second, activated pericytes expressing NGFR may detach from endothelial 
cells, migrate into the adventitia and continue to expand there. Pericyte 
proliferation in SSc (461, 462) is consistent with their progenitor potential (453). 
This proliferation may be, in part, due to increased expression and signaling 
through PDGFRβ in pericytes in the skin of SSc patients (346, 463, 464). 
Especially around small vessels, where there is little, if any, media between the 
intima and adventitia, asymmetric division of pericytes would place one of the 
daughter cells in the PA. Expansion of ADAM12-expressing pericytes has also 
  
110 
been noted in SSc (465). In mice, rare ADAM12+ pericyte-like cells proliferated 
and migrated into the dermis where they deposited ECM. These ADAM12+ cells 
increased expression of NGFR during and after expansion (163), similar to our 
data from murine skin wounds. While pericyte activation and detachment may be 
responsible for the appearance of NGFR+ PA cells around small vessels, this 
seems less likely around larger arteries where movement through thick a thick 
media layer would be necessary to reach the adventitia. Additional 
experimentation will be necessary to discern if any of these three hypotheses is 
occurring in the skin of SSc patients. 
How might PA fibroblast NGFR signaling influence SSc pathology? Ligand-
independent NGFR signaling was necessary for the conversion of hepatic stellate 
cells into myofibroblasts in a murine model of liver injury. The authors formed this 
conclusion based on data using NGFR knockout fibroblasts transduced with either 
full-length NGFR or a construct expressing only the intracellular domain (388). 
However, this may not have been truly ligand independent as the NGFR 
intracellular domain potentiates Trk-induced Akt activity, and nerve growth factor 
signaling through TrkA and NGFR induces myofibroblast conversion in dermal 
fibroblasts (352, 354, 466). NGFR signaling can also be pro-apoptotic, which has 
an important role in controlling transit amplifying cell expansion (343). Pro-nerve 
growth factor binding to NGFR has similar apoptosis-inducing effects in pericytes 
in murine models of diabetic retinopathy, erectile dysfunction and myocardial 
infarction (392, 467–471). These examples highlight the complicated signaling 
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system in which NGFR participates. Understanding the effects of NGFR on PA 
fibroblasts in SSc and healing wounds will require a thorough analysis of the other 
neurotrophin receptors expressed by these cells, the neurotrophins secreted in the 
skin of these patients and the maturation status of these ligands. 
The restriction of NGFR to the vascular unit in SSc and human scars 
contrasted with the diffuse distribution in murine scars (163) and some human 
fibromas (472–474). Perhaps NGFR+ fibromas have found a way to subvert pro-
apoptotic NGFR signaling. Or, NGFR expression could indicate that these 
fibromas are trapped in a transit amplifying state, similar to the block in 
differentiation seen in acute promyelocytic leukemia (475, 476). Following this 
logic, the NGFR+ PA fibroblasts in SSc may be differentiating in response to 
damage signals, or these cells could be undergoing pro-NGF-mediated apoptosis. 
Determining why mesenchymal cells in some settings express NGFR throughout 
the dermis, and why mesenchymal NGFR is spatially limited in other settings may 
illuminate the pathogenesis of these diseases. 
Limitations 
There are ample data demonstrating that fibroblasts can create 
microenvironments supporting T cell accumulation in the literature (111, 139, 164, 
166, 167, 477–479). The experiments provide evidence that VCAM1+ PA 
fibroblasts may retain T cells around blood vessels in DLE and dermatitis. Another 
study has indicated that macrophages and DCs can promote perivascular T cell 
accumulation (185). Both macrophages and DCs are found in the PA (73). These 
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studies do not exclude macrophages and DCs from being important drivers of 
perivascular T cell infiltration. 
Expansion of NGFR-expressing PA fibroblasts was associated with 
conditions featuring fibroblast proliferation and ECM deposition. Yet, neither the 
function of NGFR on PA fibroblasts, nor the contributions of these cells to PA 
growth or remodeling were directly demonstrated. Published roles for NGFR on 
mesenchymal cells include blocking the differentiation of progenitor cells, 
promoting the myofibroblast conversion, supporting the HIF1α-driven hypoxia 
response and inducing apoptosis (343, 365, 366, 370, 388, 389, 459, 480). All of 
these are potentially relevant to SSc, wound healing and fibromas. Neurotrophin 
signaling is complex, and elucidating which of these functional outcomes is 
relevant to SSc PA thickening will require an additional study. 
Conclusions are strengthened by obtaining concordant results through 
independent means. Confirming increased VCAM1 expression and T cell 
infiltration in DLE by both immunohistochemistry and whole-biopsy RNA 
microarrays is an example of this. Due to several restrictions, not all of the results 
from these studies were orthogonally confirmed. Using these same tools to 
validate the expanded NGFR+ PA fibroblast population in SSc was infeasible as 
many cells in the skin express this protein (326, 473). Such support will require 
isolating PA fibroblasts expressing NGFR for either bulk or single-cell RNA or 
protein analysis. Despite these limitations, these studies present a coherent 
introduction to the potential importance of PA fibroblasts in human skin diseases.
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APPENDIX: COPYRIGHT PERMISSION 
CHAPTERS TWO (METHODS) and THREE (PERIVASCULAR ADVENTITIAL 
FIBROBLAST SPECIALIZATION ACCOMPANIES T CELL RETENTION IN THE INFLAMED 
HUMAN DERMIS) 
Data and portions of the text in these chapters were originally published as: 
Barron, A. M. S., Mantero, J. C., Ho, J. D., Nazari, B., Horback, K. L., Bhawan, J., 
Lafyatis, R., Lam, C., and Browning, J. L. (2019) Perivascular Adventitial Fibroblast 
Specialization Accompanies T Cell Retention in the Inflamed Human Dermis. 
Journal of immunology (Baltimore, Md.: 1950). 202, 56–68.   
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